

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 October 2003 (30.10.2003)

PCT

(10) International Publication Number
WO 03/089474 A1

(51) International Patent Classification⁷: **C07K 16/40**, C12N 9/12, G01N 33/53, 33/573

(21) International Application Number: PCT/US03/12380

(22) International Filing Date: 21 April 2003 (21.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: *22 Oct 04*
60/375,094 22 April 2002 (22.04.2002) US

(71) Applicant (for all designated States except US): **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; 1111 Franklin Street, 12th Floor, Oakland, CA 94607 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHEN, David, J.** [US/US]; 21 Tamarisk, Moraga, CA 94556 (US). **CHAN, Doug, W.** [CA/US]; 8450 Cambridge Street #3213, Houston, TX 77054 (US). **CHEN, Ping-Chi, Benjamin** [—/US]; 30 Panoramic Way, Walnut Creek, CA 94595 (US).

(74) Agent: **CHEW, Michelle, S.**; Lawrence Berkeley National Laboratory, One Cyclotron Road, MS-90B0104, Berkeley, CA 94720 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/089474 A1

(54) Title: DNA DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT PHOSPHORYLATION SITES AND ANTIBODIES THERETO

(57) Abstract: The identification and use of two major DNA-PKcs autophosphorylation sites, Threonine (T) 2609 and Serine (S) 2056, including antibodies specific for phosphorylated T2609 and S2056. Peptides and polynucleotides encoding same, that feature these two sites of phosphorylation. The antibodies do not bind to the unphosphorylated DNA-PKcs protein or peptide, thus providing diagnostic tools to monitor the effectiveness of treatments which target the DNA repair pathway of cancer cells, and the ability to intervene or inhibit in phosphorylation of T2609 or S2056, either through application of a drug or an antibody, to increase the radiosensitivity of cancer cells.

**DNA DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
PHOSPHORYLATION SITES AND ANTIBODIES THERETO**

CROSS-REFERENCE TO RELATED APPLICATIONS

- 5 [001] This application claims priority to U.S. Provisional Patent Application No. 60/375,094, which was filed on April 22, 2002, which is incorporated by reference in its entirety.

STATEMENT REGARDING SEQUENCE LISTING

- [002] Applicants assert that the attached paper copy of the Sequence Listing for the utility application, "DNA Dependent Protein Kinase Catalytic Subunit Phosphorylation Sites and Antibodies Thereto," claiming priority to U.S. Provisional Patent Application No. 60/375,094, filed on April 21, 2003, is identical to the Sequence Listing in computer readable form found on the accompanying computer disk, as required by 37 CFR 1.821(c) and is hereby incorporated by reference in its entirety.

15

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

- [003] This invention generally relates to the field of cancer treatment, therapeutics and diagnostics. More specifically, the invention describes antibodies and a method useful for increasing the radiation sensitivity of cancer cells. The invention also provides methods of designing inhibitors of DNA-PKcs that are more specific and result in less harmful side effects.

DESCRIPTION OF THE RELATED ART

- 25 [004] In the clinical setting, the two most common treatments for cancer patients are a drug regimen or treatment with high doses of radiation, or a combination of both. Both approaches kill cancerous (and healthy) cells through a common mechanism of inducing DNA damage. DNA double-strand breaks (DSB) are the most common type of DNA damage resulting from either treatment. In human cells, DNA DSBs are repaired mainly by 30 the non-homologous end-joining pathway (NHEJ). The DNA-dependent protein kinase complex (DNA-PK) is a key player in the repair of DNA DSBs by this pathway. If DNA-PK is defective, cells are unable to repair DNA DSBs, and thus become highly sensitive to the

effects of ionizing radiation and of various cancer drugs. Since DNA-PK is a protein kinase, it is able to transfer phosphate groups to target proteins, and thereby regulate their function. DNA-PK is a protein complex consisting of its DNA-binding and regulatory subunit, which is the Ku protein, and the catalytic subunit, called DNA-PKcs. In the presence of DNA 5 DSBs, Ku binds to the ends of the DNA and recruits DNA-PKcs to the site of the DSB. Once bound to Ku and DNA, DNA-PKcs becomes activated and is capable of phosphorylating target proteins.

[005] Although the biochemical properties of DNA-PK have been extensively studies *in vitro*, very little is known about how DNA-PK functions *in vivo* in relation to the 0 repair of DNA DSBs. This lack of progress in studying the physiological functions of DNA-PK is in part due to the unavailability of the right tools or assays to evaluate DNA-PK *in vivo* activity.

[006] Currently, one of the most commonly used methods to study DNA repair 5 proteins is by immunofluorescence with an antibody to the protein of interest. In response to DNA damage, many of the DNA repair proteins form "foci" that can be visualized with .5 antibodies. It is generally believed that these DNA damage-induced foci correspond to sites where the damaged DNA is actively being repaired.

[007] It is currently not possible to detect DNA-PK foci with the antibodies available because DNA-PK is quite abundant in the nucleus, thus when one performs 20 immunofluorescence with any of the available antibodies, the entire nucleus will produce a signal, making it impossible to see any discernable foci. Therefore, it is of interest to develop an antibody that can overcome the problem associated with a very high background signal and can recognize the phosphorylated form of DNA-PKcs when bound to site of DNA DSBs.

[008] DNA-PK is a serine/threonine protein kinase that *in vitro* is activated by DNA 25 ends and has long been established to play an important role in the repair of DNA double-strand breaks (DSB) by the NHEJ pathway (Smith and Jackson, *Genes Dev.* 1999 Apr 15;13(8):916-34). DNA-PK is capable of autophosphorylating the two Ku subunits, Ku70 and Ku80 according to Chan et al., *Biochemistry* 1999 Feb 9;38(6):1819-28. Autophosphorylation of DNA-PKcs causes it to dissociate from Ku, resulting in the loss of 30 kinase activity (Chan and Lees-Miller, *J Biol Chem.* 1996 Apr 12;271(15):8936-41). In addition, the inventors have shown that the kinase activity of DNA-PKcs is absolutely required for its function in the NHEJ pathway since a DNA-PKcs-deficient CHO cell line expressing a kinase dead form of DNA-PKcs was incapable of repair (Kurimasa et al., *The Journal of Immunology*, 2000, 165: 3883-3889). Therefore, the kinase activity of DNA-PK is

absolutely required for the repair of DNA DSBs; however, the molecular mechanism of this requirement for kinase activity remains to be elucidated. DNA-PK is also capable of autophosphorylation, that is, it transfers phosphate groups onto itself, and that autophosphorylation may be an important mechanism for regulating its kinase activity
5 (Kurimasa et al., *Molecular and Cellular Biology*, May 1999, p. 3877-3884, Vol. 19, No. 5).

[009] DNA-PKcs is an extremely large protein consisting of 4129 amino acids, and therefore identifying the site of autophosphorylation is comparable to finding a very small needle in a large haystack. Cloning of the DNA-PKcs cDNA is difficult, since the cDNA exceeds 13 kb. In the past, using classical biochemical techniques, several labs have
10 attempted but failed to identify the autophosphorylation sites. For example, *in vivo* radiolabelling with ^{32}P and 2-dimensional phosphopeptide mapping failed to identify any autophosphorylation sites.

[010] One goal of radiation biology is to find ways to increase the radiation sensitivity of cancer cells. If this could be achieved, it would then be possible to treat cancer
15 patients with lower doses of radiation and thereby dramatically decrease the side effects and complications associated with radiation treatment.

[011] If the site of phosphorylation in DNA-PK could be specifically blocked in cancer cells, for example with a DNA-PKcs inhibitor, then this should inhibit DNA-PKcs-mediated repair of DNA DSBs and thereby increase the radiation sensitivity of the treated
20 cancer cells. Another possible means of increasing radiation sensitivity is the development of therapeutic antibodies that can specifically recognize and bind to the phosphorylated protein.

BRIEF SUMMARY OF THE INVENTION

[012] The present invention is directed to the identification and use of two major
25 DNA-PKcs autophosphorylation sites, Threonine (T) 2609 and Serine (S) 2056, including antibodies specific for phosphorylated T2609 and S2056. It is demonstrated that phosphorylation of these sites, carried out *in vivo* by the DNA-PKcs itself (i.e. autophosphorylation), is required for DNA-PK activity and, furthermore, that such activity repairs double strand DNA breaks (DSBs) and improves cell survival to ionizing radiation
30 (IR). For example, it is demonstrated a point mutation at position 2056 from serine to alanine and position 2609 from threonine to alanine results in cells that are radiosensitive.

[013] The present invention further provides phosphospecific antibodies that recognize these specific sites of phosphorylation in DNA-PKcs. The antibodies do not bind to the unphosphorylated DNA-PKcs protein or peptide. This provides diagnostic tools based

on the ability to identify the phosphorylation status of the DNA-PKcs autophosphorylation sites. One can monitor the effectiveness of treatments which target the DNA repair pathway of cancer cells, such as radiation treatment and inhibitor drugs. Also, the ability to intervene in autophosphorylation of T2609 or S2056, either through application of a drug or an antibody, would increase the radiation-induced killing of cancer cells.

5 [014] In one embodiment there is provided an antibody which specifically binds to an epitope defined by at least a ten amino acid sequence from DNA-PKcs and comprising a phosphorylated threonine at position T2609 in human DNA-PKcs, which antibody does not bind when T2609 is not phosphorylated. The antibody may be an affinity purified polyclonal antibody or a monoclonal antibody. The monoclonal may be a conventional hybridoma produced mouse monoclonal, or may be a human monoclonal produced by known techniques. In one embodiment, the human monoclonal is produced using a mouse with a human immune system as an immune cell donor in a hybridoma process. One specific embodiment is the pT2609 monoclonal antibody, pT2609mAb.

5 [015] The invention further comprises an antibody which specifically binds to an epitope defined by at least a ten amino acid sequence from DNA-PKcs and comprising a phosphorylated serine at position S2056 in human DNA-PKcs, which antibody does not bind when S2056 is not phosphorylated. Again, the antibody may be an affinity purified polyclonal antibody or a monoclonal antibody. The monoclonal may be a conventional hybridoma produced mouse monoclonal, or may be a human monoclonal produced by known techniques. In one embodiment, the human monoclonal is produced by using a mouse with a human immune system as an immune cell donor in a hybridoma process. One specific embodiment is the pS2056 monoclonal antibody, pS2056mAb.

25 [016] In any case, the binding epitope is contained both on full length DNA-PKcs and subsequences thereof, said subsequences having at least about 10 amino acids.

30 [017] The present invention further comprises methods for determining the ability of a test compound to block phosphorylation of human DNA-PKcs. One method comprising the following steps: (a) providing a sample containing a DNA-PKcs peptide fragment capable of being phosphorylated; (b) adding the test compound to the sample; (c) inducing phosphorylation of the DNA-PKcs protein in the sample; and (d) measuring the resulting phosphorylation of DNA-PKcs at T2609 or S2056 in the presence of the test compound. This is preferably done in comparison to a sample containing a DNA-PKcs peptide fragment which is phosphorylated in the absence of the test compound.

[018] The method may also involve providing a sample containing an artificial peptide containing the T2609 and/or S2056 site. Recombinant DNA-PK or DNA-PKcs is added to the mixture and will phosphorylate the artificial peptide. The artificial peptide may be on the order of about 1000 amino acids long or as short as 20 amino acids long.

5 [019] The measuring step may be carried out by measuring the binding of an antibody which specifically binds to an epitope comprising either or both of (a) a phosphorylated serine at position S2056 in human DNA-PKcs or (b) a phosphorylated threonin at position T2609 in human DNA-PKcs

0 [020] Known kinase inhibitors provide suitable starting points for assaying test compounds that are capable of blocking or inhibiting phosphorylation of DNA-PKcs. In this assay, test compounds are any organic molecules that are capable of blocking or inhibiting phosphorylation of DNA-PKcs. Non-limiting examples include wortmannin, substituted or unsubstituted imidazoles, pyrazoles, benzofluoranthenes, thiazoles, isoquinolinones, dihydrolisoquinolinones, phthalazinones and related compounds and derivatives thereof. For example, since wortmannin has been shown herein to inhibit the phosphorylation of T2609 and S2056, derivatives and analogs of wortmannin provide sources of test compounds to be tested in the present assay. Functional groups could be introduced into the wortmannin structure adjacent to the heterocyclic oxygen adjacent to C21 or the double bond between C4 and C21.

20 [021] To identify drug inhibitors of DNA-PK, one first initially screens available chemical libraries for test compounds that could inhibit DNA-PK kinase activity *in vitro* or organic molecules that are capable of blocking or inhibiting phosphorylation of DNA-PKcs. The compounds in these chemical libraries can be added to *in vitro* DNA-PK kinase assays to identify the ones that could inhibit DNA-PK activity. Because phosphorylation of T2609 and S2056 is via an autophosphorylation mechanism, it can be speculated that any drug compounds that inhibit the kinase activity will inhibit the autophosphorylation of these two sites. Once these compounds have been identified, cellular studies can then be carried out to evaluate their efficacy.

30 [022] Further aspects of the present invention involve phosphopeptides that have been prepared for use in injection into animals in the course of antibody preparation (haptens) or for use as artificial phosphorylation substrates. These peptides will have less than 30 amino acids and comprise SEQ ID NO: 1 or SEQ ID NO: 2, or sequences having at least 90% homology thereto having the requisite serine or threonine residues, preferably in an SQ or TQ

sequence. These phosphopeptides may also have an amino acid other than the wild type T2609 or S2056, to serve as negative controls.

[023] The above described isolated peptides have further utility when T2609 and/or S2056 is replaced by an amino acid which is not phosphorylated, such as: Valine, Alanine,

5 Glycine, or Leucine. These embodiments serve as negative controls and will inhibit phosphorylation.

[024] The above described peptides may be encoded by an isolated polynucleotide cloned and inserted into a suitable host vector.

[025] The present invention further comprises a method of measuring

0 radiosensitivity of cells in a subject undergoing radiation treatment. This method comprises the steps of (a) providing a cell sample from said subject and containing DNA-PKcs, for example a blood sample or a tissue sample from the irradiated area (e.g. a nuclear extract may be prepared from this sample); (b) adding to said sample a labeled antibody which binds to phosphorylated residue T2609 or phosphorylated residue S2056 but not the unphosphorylated residues; (c) removing unbound antibody from the sample, such as by washing, as is known in the art; and (d) measuring the degree of phosphorylation of the DNA-PKcs by determining the amount of antibody bound to the DNA-PK in the sample. The degree of antibody binding to DNA-PKcs in the cell sample correlates to the degree of phosphorylation, a higher degree of phosphorylation indicating less radiation sensitivity

15 [026] Since most treatment for cancer entails inducing DNA damage, a pT2609 or pS2056 antibody can be a very useful diagnostic tool for determining the efficacy of the treatment. For example, the antibody can be used to confirm that the cancer treatment is indeed causing DNA damage in the cancer cells; conversely, the antibody can be used to determine the effects of the treatment on healthy cells.

25

BRIEF DESCRIPTION OF THE DRAWINGS

[027] Fig. 1 is a mass spectra of sequencing of the *in vitro* phosphorylated DNA-PKcs peptide that was first identified by MALDI-TOF mass spectrometry. The plot shows a plot of relative intensity *vs* the mass-to-charge ratio (m/z) of the phosphorylated peptide having the shown sequence from 2599 to 2619. Assignment of all the mass spectra peaks unequivocally identify T2609 as the site of phosphorylation.

30 [028] Fig. 2 is the mass spectra of phosphatase-treated (bottom trace) and the mock treated (top trace) DNA-PKcs peptides from irradiated HeLa cells which were purified by immunoprecipitation and digested with Asp-N protease, then analyzed by MALDI-TOF mass

spectrometry. The loss of the peak with the m/z of 3511 with phosphatase treatment, and the presence of the peak corresponding to the unphosphorylated peptide (m/z of 3433) allowed the positive assignment of a phosphorylation site to the sequence of DNA-PKcs between amino acids 2044-2072.

5 [029] **Fig. 3A** is a Western blot showing DNA-PKcs protein expression levels of vector along (V3-JM), full-length wild-type DNA-PKcs (V3-F18) and T2609A mutant of DNA-PKcs in V3 cell line (top). Hamster Werner proteins were analyzed to show equal sample loading (bottom). **Fig. 3B** is a graph showing that the T2609A, S2056A and the T2609A/S2056A double mutation increase cellular radiation sensitivity. **Fig. 3C** is a graph 10 showing that the T2609A and S2056A mutations compromise DSB repair in cells as determined by the fraction of activity released (FAR) assay.

[030] **Fig. 4A** is two Western blots showing that the pT2609pAb is specific for the phosphorylated T2609 site in wild type DNA-PKcs. **Fig. 4B** is two Western blots showing that the pT2609 polyclonal antibody (pT2609pAb) does not recognize unphosphorylated DNA-PKcs at the molar ratios given as compared to 25-4 DNA-PKcs monoclonal antibody (25-4 mAb). **Fig. 4C** is two Western blots showing that the pS2056 polyclonal antibody (pS2056pAb) does not recognize unphosphorylated S2056 in DNA-PKcs as compared to 25-4 DNA-PKcs monoclonal antibody (25-4 mAb).

[031] **Fig. 5A** is a Western blot of Hela cell nuclear extracts, probed with pT2609 antibody (upper panel) and 25-4 monoclonal antibody to DNA-PKcs (bottom panel), after either mock-treatment or irradiation with 10 Gy and recovery for various times. **Fig. 5B** is a Western blot of Hela cell nuclear extracts, probed with pT2609pAb (upper panel) and 25-4 monoclonal antibody to DNA-PKcs (bottom panel), after irradiation at the indicated dose and recovery for 30 minutes. **Fig. 5C** is a Western blot showing that pT2609 polyclonal antibody 25 can be used to immunoprecipitate phosphorylated DNA-PKcs from unirradiated HeLa nuclear extract (lane 1) but not unphosphorylated DNA-PKcs from extracts made from HeLa cells irradiated with 25 Gy and harvested after 30 min recovery period. The 25-4 monoclonal antibody does not discriminate between phosphorylated or unphosphorylated DNA-PKcs. **Fig. 5D** shows by Western blot that phosphorylation of T2609 in response to DNA damage 30 can be inhibited with wortmannin treatment (left panel) and is inducible in A-T cells (right panel).

[032] **Fig 6A** is a Western blot showing that phosphorylation of S2056 is IR-inducible. **Fig. 6B** is a time course Western blot of IR-inducible phosphorylation of Ser 2056.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT**A. Definitions**

- [033] "Radiosensitization" herein refers to a means of increasing the sensitivity of 5 human cells to the effects of ionizing radiation and cancer drugs that induce DNA double-strand breaks (DSBs). By increasing the radiosensitivity of cancer cells, patients can be treated with lower doses of radiation or chemotherapeutic regimen and thereby decrease the harmful side effects of the treatment.
- [034] "Gy" herein refers to describe the unit (SI unit) of absorbed dose of radiation 10 (Gy), wherein $1 \text{ Gy} = 1 \text{ J kg}^{-1} = 100 \text{ rad}$.
- [035] "Epitope" has its conventional meaning, i.e. a single antigenic determinant. Functionally it is the portion of an antigen (e.g. a PKcs peptide) which combines with the antibody paratope. Structurally, it is the specific amino acid residues or portions thereof to which an anti-peptide antibody binds.
- 15 [036] "DNA-PKcs" herein refers to DNA-dependent protein kinase catalytic subunit (EC 2.7.1.37), preferably human DNA-PKcs. As used herein, the numbering is based on GenBank Accession Number P78527, as set out in SEQ ID NO: 3. Specifically, T2609 is threonine 2609 in Genbank Accession Number P78527. S2056 is serine 2056 in GenBank Accession Number P78527. DNA-PK refers to the entire enzyme. DNA-PKcs is encoded by 20 the nucleotide sequence as set out in SEQ ID NO: 15, having GenBank Accession Number U47077.
- [037] "Monoclonal antibody" has its conventional meaning, and is explained more fully in U.S. patent 4,619,895, hereby incorporated by reference for purposes of describing preparation and characterization of mouse monoclonal antibodies, U.S. patent 4,744,982 25 hereby incorporated by reference for purposes of describing human/human monoclonal antibody preparation and characterization, U.S. patent 5,874,540, hereby incorporated by reference for purposes of describing the preparation and characterization of CDR-grafted humanized antibodies, and U.S. patent 6,075,181, hereby incorporated by reference for purposes of describing the preparation and characterization of human antibodies derived from 30 immunized xenomice.
- [038] The abbreviation "mAb" herein refers to monoclonal antibodies and the abbreviation "pAb" herein refers to polyclonal antibodies.

[039] "Humanize," when applied to antibodies, herein refers to methods of generating human monoclonal antibodies, as exemplified by van de Winkel, in U.S. Pat. No. 6,111,166, hereby incorporated by reference for purposes of describing such methods.

[040] "Isolated," when applied to a polynucleotide, herein refers to that the 5 polynucleotide has been removed from its natural genetic milieu and is thus free of the extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems. Such isolated molecules are those that are separated from their natural environment and include cDNA, synthetic DNA and genomic clones. Isolated DNA molecules of the present invention are free of other genes with which they are 10 ordinarily associated, but may include naturally occurring 5' and 3' untranslated regions such as promoters and terminators. The identification of associated regions will be evident to one of ordinary skill in the art (see for example, Dynan and Tijan, *Nature* 316:774-78, 1985).

[041] "Isolated," when applied to a polypeptide or protein, herein refers to a 15 polypeptide or protein that is found in a condition other than its native environment, such as apart from blood and animal tissue. In a preferred form, the isolated polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin. It is preferred to provide the polypeptides in a highly purified form, i.e. greater than 95% pure, more preferably greater than 99% pure. When used in this context, the term "isolated" does not exclude the presence of the same polypeptide in alternative physical forms, such as 20 dimers or alternatively glycosylated or derivatized forms.

[042] "Polynucleotide" herein refers to a single- or double-stranded polymer of 25 deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized in vitro, or prepared from a combination of natural and synthetic molecules. Sizes of polynucleotides are expressed as base pairs (abbreviated "bp"), nucleotides ("nt"), or kilobases ("kb"). Where the context allows, the latter two terms may describe polynucleotides that are single-stranded or double-stranded. When the term is applied to double-stranded molecules it is used to denote overall length and will be understood to be equivalent to the term "base pairs". It will be recognized by those skilled in the art that the two strands of a double-stranded polynucleotide 30 may differ slightly in length and that the ends thereof may be staggered as a result of enzymatic cleavage; thus all nucleotides within a double-stranded polynucleotide molecule may not be paired. Such unpaired ends will in general not exceed 20 nt in length.

[043] "Polypeptide" herein refers to a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as "peptides".

[044] "Homologous" herein refers to the sequence similarity between two polymeric molecules, e.g., between two nucleic acid molecules, e.g., two DNA molecules or two RNA molecules, or between two peptide molecules. When a subunit position in both of the two molecules is occupied by the same monomeric subunit, e.g., if a position in each of two DNA molecules is occupied by adenine, then they are homologous at that position. The homology between two sequences is a direct function of the number of matching or homologous positions, e.g., if half (e.g., five positions in a polymer ten subunits in length) of the positions in two compound sequences are homologous then the two sequences are 50% homologous, if 90% of the positions, e.g., 9 of 10, are matched or homologous, the two sequences share 90% homology. By way of example, the DNA sequences 3' ATTGCC 5' and 3' TATGCG 5' share 50% homology. Any of a variety of known algorithms may be used to calculate the percent homology between two nucleic acids or two proteins of interest and these are well-known in the art.

[045] "Substantial homology" or "substantial identity", when referring to polypeptides, herein refers to that the polypeptide or protein in question exhibits at least about 30% identity using BLASTP (Altschul, S.F., Gish, W., Miller, W., Myers, E.W. & Lipman, D.J. (1990) "Basic local alignment search tool." *J. Mol. Biol.* 215:403-410) with an entire naturally-occurring protein or a portion thereof, usually at least about 70% identity over the common lengths, more usually at least about 80% identity, preferably at least about 90% identity, and more preferably at least about 90% identity or 90% positive, whichever is less. For purposes of calculating homology between two polypeptides, the standard BLASTP 2.2.5 defaults are used, namely "Expect 10," "Word size 3," "BLOSUM62 Matrix" and "Gap Costs Existence10, Extension 1."

[046] In this specification, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.

B. Role of DNA PK-cs in Double Strand Break Repair

[047] Repair of DNA double strand breaks (DSBs) in mammalian cells is mainly mediated by the non-homologous end-joining pathway (NHEJ). The DNA-dependent protein kinase (DNA-PK) complex play critical roles in the NHEJ pathway since mammalian

cell lines that lack components of the complex show severe radiation sensitivity and DNA repair defects. DNA-PK is a serine/threonine protein kinase that is activated by the DNA ends *in vitro* and is composed of the DNA-binding and regulatory subunit, Ku, and the catalytic subunit, DNA-PKcs. DNA-PK kinase activity is required for the repair of DNA 5 DSBs *in vivo* (Kurimasa et al., *Mol Cell Biol.* 1999 May; 19(5):3877-84). Previously, it was demonstrated that DNA-PK activity is negatively regulated by an autophosphorylation mechanism *in vitro*. (Chan et al., *Biochem Cell Biol* 74: 67-73, 1996).

[048] In the preferred embodiment, the DNA-PKcs being investigated has an amino acid sequence comprising SEQ ID NO: 3 and wild-type cDNA sequence comprising SEQ ID 10 NO: 15.

[049] Herein is reported the method and identification of residues of DNA-PKcs which can act as major *in vitro* and *in vivo* autophosphorylation sites.

C. Autophosphorylation Sites in DNA-PKcs

[050] Determination of autophosphorylation sites in DNA-PKcs is preferably done 15 by mass spectrometry. For example, purified DNA-PKcs and Ku can be autophosphorylated by adding a low concentration of ATP to allow phosphorylation of the most preferential site and then the autophosphorylated DNA-PKcs was analyzed by mass spectrometry. Alternatively, DNA-PKcs can be immunoprecipitated from nuclear extracts prepared from irradiated HeLa cells and then analyzed by mass spectrometry.

[051] As described below, two major *in vitro* and *in vivo* autophosphorylation sites 20 of the residues of T2609 and S2056 were identified by mass spectrometry. Purified DNA-PKcs and Ku were autophosphorylated with low concentration of ATP (50uM) to allow phosphorylation of the most preferential site. Referring now to Fig. 1, the *in vitro* autophosphorylated DNA-PKcs was analyzed by mass spectrometry and T2609 was 25 unambiguously identified as a major site of autophosphorylation. T2609 lies in a region of DNA-PKcs that is not conserved between the various members of the phosphatidylinositol 3-kinase (PI-3) family members, to which DNA-PKcs is a member of. However, T2609 was absolutely conserved in all known DNA-PKcs homologues found in GenBank (i.e. mouse, dog, horse, chicken and xenopus) when the sequences are compared. This suggests the 30 significance of the phosphorylation of this residue and that phosphorylation of DNA-PKcs at this residue maybe be conserved throughout evolution.

[052] Referring now to Fig. 2, a second major *in vitro* and *in vivo* autophosphorylation site of DNA-PKcs, S2056, was identified by immunoprecipitating DNA-PKcs from nuclear extracts prepared from irradiated HeLa cells and analyzed by mass

spectrometry. As described in detail below, mass spectrometry identified the following phosphopeptide sequence, DFSTGVQSYSQDPRPATGRFRRREQR (SEQ ID NO: 5), which corresponds to amino acids 2044 to 2072 of DNA-PKcs (S2056 is underlined). Upon careful analysis of the sequence, S2056 proved to be the site of phosphorylation. This is
5 consistent with prior suggestions that DNA-PK preferentially phosphorylates "SQ" and "TQ" sequences and S2056 followed this "SQ" consensus sequence. Similar to T2609, the sequence alignment with other vertebrate DNA-PKcs homologues in GenBank shows that amino acids 2044 to 2056 in DNA-PKcs are highly conserved throughout evolution in vertebrates.

10 D. Role of DNA-PKcs Autophosphorylation Sites in Radiation Sensitivity

[053] To investigate the biological significance of the autophosphorylation of these DNA-PKcs sites in relation to DNA repair, wild-type or mutant DNA-PKcs having the site of autophosphorylation mutated were transfected into the DNA-PKcs-defective V3 cell line (Kurimasa et al., *J Immunol.* 2000 Oct 1;165(7):3883-9). The resulting V3 cell lines were
15 isolated and evaluated for DNA-PKcs protein expression levels, radiation sensitivity, and DNA repair defects. Cells expressing the mutant DNA-PKcs protein exhibit a more severe radiation sensitivity phenotype as compared with wild-type DNA-PKcs protein yet not as severe as the V3 cell line that totally lacks DNA-PKcs. The V3-mutant DNA-PKcs cells exhibits a radiation sensitivity phenotype of about a 10 fold increase in cell death at 5 Gy
20 when compared with V3-wild type cells, demonstrating a dramatic difference in radiation sensitivity in mammalian cells.

E. Generation of anti-pT2609 and anti-pS2056 phosphospecific antibodies

[054] To study the *in vivo* phosphorylation status of DNA-PKcs at the autophosphorylation sites, a phosphospecific antibody that recognizes the phosphorylated residue of DNA-PKcs is generated, then affinity purified to insure specificity.

[055] DNA-PKcs phosphospecific antibodies can be made by a number of methods known in the art. These phosphospecific antibodies include antibodies which recognize phosphorylated T2609, herein referred to as pT2609 antibodies and phosphorylated S2056, herein referred to as pS2056 antibodies. A preferred method is by generating phosphopeptides. These phosphopeptides can be synthesized or produced by first amplifying and cloning cDNA fragments of SEQ ID NO: 15, the cDNA sequence of human DNA-PKcs (GenBank Accession No. U47077), and then expressing peptide fragments of DNA-PKcs from the cloned cDNAs. These phosphopeptide fragments include the site of

autophosphorylation and the adjacent DNA-PKcs amino acid sequence on either side of the position being autophosphorylated. It is preferred that at least 6, preferably no more than 10 amino acids of the wild-type DNA-PKcs protein sequence are used on either side of the phosphorylation site to generate very specific antibodies. Two such preferred 5 phosphopeptides are SEQ ID NO: 1 and 2 and shown below.

SEQ ID NO: 1 N' -- TPMFVET*QASQGTC--C' (* indicating phospho group at T2609)

SEQ ID NO: 2 N' -- QSYSYSS*QDPRPAC--C' (* indicating phospho group at S2056)

[056] Since synthesized phosphopeptides are not always immunogenic on their own, the peptides were conjugated to a carrier protein before use. Appropriate carrier proteins 10 include, but are not limited to, Keyhole limpet hemacyanin (KLH), bovine serum albumin (BSA) and ovalbumin (OVA). The conjugated phosphopeptides should then be mixed with adjuvant and injected into a mammal, preferably a rabbit through intradermal injection, to elicit an immunogenic response. Samples of serum can be collected and tested by ELISA assay to determine the titer of the antibodies and then harvested.

15 [057] Polyclonal pT2609 and pS2056 antibodies can be purified by passing the harvested antibodies through an affinity column. However, monoclonal antibodies are preferred over polyclonal antibodies and can be generated according to standard methods known in the art of creating an immortal cell line which expresses the antibody.

[058] Nonhuman antibodies are highly immunogenic in human thus limiting their 20 therapeutic potential. In order to reduce their immunogenicity, nonhuman antibodies need to be humanized for therapeutic application. Through the years, many researchers have developed different strategies to humanize the nonhuman antibodies. One such example is using "HuMAb-Mouse" technology available from MEDAREX, Inc. (Princeton, NJ). "HuMAb-Mouse" is a strain of transgenic mice that harbors the entire human immunoglobulin 25 (Ig) loci and thus can be used to produce fully human monoclonal pT2609 and pS2056 antibodies.

[059] Immunoblotting using the phosphospecific antibodies of the invention with unphosphorylated DNA-PKcs should not produce a detectable signal at preferably 0.5-10 fold molar excess (relative to the phosphorylated DNA-PKcs), more preferably at 50 fold molar 30 excess and most preferably no signal is detected at even 100 fold molar excess.

F. Designing and Making DNA-PKcs Inhibitor Drugs

[060] The phosphorylation of DNA-PKcs at Threonine 2609 and Serine 2056 is required for the repair of DNA double strand breaks. By inhibiting the phosphorylation of

these two sites with small molecules, it may be possible to increase the radiation-induced killing of cancer cells.

[061] To identify drug inhibitors of DNA-PK, one first initially screens available chemical libraries for test compounds that could inhibit DNA-PK kinase activity *in vitro* or 5 organic molecules that are capable of blocking or inhibiting phosphorylation of DNA-PKcs. Analysis of known kinase inhibitors provides suitable starting points and non-limiting examples, include wortmannin, substituted or unsubstituted imidazoles, pyrazoles, benzofluoranthenes, thiazoles, isoquinolinones, dihydrolisoquinolinones, phthalazinones and related compounds and derivatives thereof. The compounds in these chemical libraries can 10 be added to *in vitro* DNA-PK kinase assays to identify the ones that could inhibit DNA-PK activity. Because phosphorylation of T2609 and S2056 is via an autophosphorylation mechanism, it can be speculated that any drug compounds that inhibit the kinase activity will inhibit the autophosphorylation of these two sites. Once these compounds have been identified, cellular studies can then be carried out to evaluate their efficacy.

[062] Amino acid peptide fragments of DNA-PKcs around the T2609 and S2056 sites were expressed in *E. coli* despite the difficulty encountered in cloning the corresponding cDNA sequence. In a preferred embodiment, the DNA-PKcs cDNA clones containing SEQ 15 ID NO: 18 and SEQ ID NO: 22, which express peptide fragments corresponding to the amino acid sequence of DNA-PKcs from residues 1879-2182 and from 2500-2700 respectively, are made. In another preferred embodiment, an 822 amino acid fragment (residues 1879-2700) 20 can be expressed from a cDNA clone containing SEQ ID NO: 20 because this fragment once expressed encompasses both phosphorylation sites.

[063] These fragments which encompass one or both phosphorylation sites can be 25 made by amplifying the appropriate cDNA sequence from a full-length DNA-PKcs cDNA (SEQ ID NO: 15, GenBank Accession No. U47077) by PCR, then cloning and expressing the cDNA sequence to generate the peptide fragment. Primers can be designed and made from SEQ ID NO: 15. It is preferred that the peptide fragment containing the phosphorylation site, be of a length of at least 10, preferably 100, and more preferably about 1000 amino acids of the DNA-PKcs protein sequence.

[064] In one embodiment, these fragments can be used to test how effectively 30 potential drugs inhibit the phosphorylation and activation of DNA-PKcs. Recombinant fragments containing these two phosphorylation sites can be used as molecular targets for small molecular screening. Specifically, small molecules which can bind to these fragments with high affinity will be identified. The inhibition capability of these small molecules can

be verified by their ability to block T2609 and S2056 phosphorylation. The radiation sensitization ability of these small molecules can then be verified in human cells upon radiation damage.

[065] In addition, fragments that may also be useful can be expressed from the following clones. These clones were made to express the following residues of DNA-PKcs from the indicated corresponding cloned cDNA sequence: 1879-2182 cDNA (SEQ ID NO: 18), 1879-2267 cDNA (SEQ ID NO: 19), 2261-2700 cDNA (SEQ ID NO: 21), 2275-2702 cDNA (SEQ ID NO: 23), 2429-2702 cDNA (SEQ ID NO: 24), 2561-2700 cDNA (SEQ ID NO: 25), and 2600-2702 cDNA (SEQ ID NO: 26).

10 G. Peptide Inhibitor Drugs

[066] One embodiment is to use the antibodies of the invention for use as an inhibitor of the phosphorylation and thereby block DNA repair which results in radiosensitization of cancer cells. Because of the specificity of the pT2609 and pS2056 antibodies of the invention, only the sites of phosphorylation are inhibited. Furthermore, phosphorylation of T2609 and S2056 occurs only in cells that have been irradiated and suffer DNA damage. Therefore, the use of the antibodies, or peptide fragments thereof, as DNA repair inhibitors will not affect other proteins or even other parts and functions of the DNA-PKcs protein. This specificity will result in not only radiosensitizing cancer cells, but also this antibody will reduce the other harmful side effects of inhibiting all DNA-PKcs function.

[067] If phosphorylation of T2609 is required for the recruitment of other proteins needed at the site of DNA DSBs, then another means of disrupting this step is to overexpress a small polypeptide spanning the region that surrounds T2609 or S2056 with an Aspartic acid mutation to simulate the phosphorylated state and create a "dominant negative" effect. Therefore, in another embodiment, a polypeptide, such as the peptides generated in Example 2, made with an Aspartic acid or other similarly negatively charged amino acid substituted at residue 2609 or 2056 to mimic the phosphorylated state of T2609, can be overexpressed or administered to compete with endogenous phosphorylated DNA-PKcs. This would "squench" DNA-PKcs function and therefore lead to an increase in radiation sensitivity.

H. Diagnostic Tools for Detecting Efficacy of Therapeutic Treatments

[068] Companies are developing specific inhibitors for DNA-PKcs or Ku for the purpose of sensitizing cancer cells for radiation therapy. Currently, there is no efficient way to estimate the amount of the inhibitors to be used for sensitization. Antibodies against T2609 or S2506 can be used as a diagnostic tool to effectively monitor blood samples in the test tube to estimate the dose to be used to effectively block the autophosphorylation of

DNA-PKcs. The present pT2609 or pS2056 antibodies can provide a diagnostic tool for determining the efficacy of treatment using DNA-PKcs or Ku inhibitors. The antibodies of the invention can be used to confirm whether the cancer treatment the patient is undergoing is indeed causing DNA damage in the cancer cells; conversely, the antibody can be used to determine the effects of the treatment on healthy cells. Furthermore, diagnostic tests to test the efficacy of inhibitors during drug development can be made based on observations of phosphorylation of T2609, such as in Example 6 or 8.

[069] In one embodiment, the antibodies of the invention can be used to determine the correct radiation dosage for each patient. The normal patient dosage is 2Gy/day up to 50 Gy/day. Since every cancer patient responds to radiation therapy differently, the pT2609 and pS2056 antibodies can be a very useful tool to monitor the effectiveness of the cancer treatment. In a specific embodiment, for example, a small blood sample is drawn from a cancer patient and a quick radiation pulse is applied to the sample to induce DNA damage, then contacting a small volume of the radiated blood with the antibodies of the invention. To increase the signal, the antibodies can be conjugated to another antibody or other means of detection used. Unbound antibodies are washed from the sample and antibodies bound to the patient's DNA-PKcs are measured. A large signal as compared to a control will indicate to an oncologist that any inhibitors that target DNA-PKcs are not working and not inhibiting DNA repair. That is, there is a high degree of DNA-PK autophosphorylation. A low or no signal would indicate that the inhibitors are working which has resulted in the radiosensitization of cancer cells. Alternatively, the blood sample is not irradiated but taken from a patient following radiation treatment to monitor the radiation therapy. In addition, the cells may be taken from a biopsy of the patient's tumor or cancer cells.

[070] In another embodiment, the peptide fragments of SEQ ID NOS: 4-14, would permit the screening of small molecular inhibitors to block phosphorylation at these sites. Small molecular inhibitors which would block the phosphorylation at T2609 or S2506 would be more effective radiosensitizers and have less side effects for radiotherapy. The reason is that the phosphorylation of these two sites only occurs after radiation or DNA damage in response to DSBs and only activated in DNA double-strand break repair. Therefore, inhibitors which are specific for these two sites should not have any effect in cells which have not been irradiated.

EXAMPLE 1

Determining T2609 and S2056 Sites of Autophosphorylation in DNA-PKcs by Mass Spectrometry

[071] First, purified human DNA-PKcs and Ku were autophosphorylated as previously described (Chan and Lees-Miller, *J Biol Chem* 271: 8936-8941, 1996), and hereby incorporated by reference, with the following change: 50 μ M ATP was used instead of 250 μ M to allow phosphorylation of the most preferential site. Purified DNA-PKcs and Ku proteins were preincubated at 30 °C. Reactions contained 25 mM Hepes, pH 7.5, 75 mM KCl, 10 mM MgCl₂, 1 mM dithiothreitol, 0.2 mM EGTA, 0.1 mM EDTA plus 10 μ g/ml sonicated calf thymus DNA, and 0.25 mM ATP containing stabilized [γ -P]ATP (Sigma Chemicals, St. Louis, MO) (specific activity, 500-1000 dpm/pmol) and were started by the addition of purified DNA-PK proteins (usually 0.05-0.1 μ g as indicated). Reactions were at 10 30 °C for 5-10 min and DNA-PK activity was calculated as nmol of phosphate incorporated into the peptide substrate per minute per milligram of protein. Unlabeled ATP or the nonhydrolyzable ATP analogue AMP-PNP (Sigma Chemicals, St. Louis, MO) were present where indicated at 50 μ M. After 0-10 min, aliquots were removed and analyzed by SDS-PAGE. The band corresponding to phosphorylated DNA-PKcs was excised and digested 15 with trypsin.

[072] The tryptic DNA-PKcs fragments were analyzed by mass spectrometry as previously described by Zhang et al., *Anal Chem* 70: 2050-2059, 1998. This procedure facilitates the identification of precise phosphorylation sites in proteins separated by polyacrylamide gel electrophoresis by a combination of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI/TOF) and on-line capillary 20 liquid chromatography electrospray tandem ion trap mass spectrometry (LC/ESI/MS/MS).

[073] To identify the DNA-PKcs *in vitro* T2609 phosphorylation site, purified DNA-PK was *in vitro* autophosphorylated under the conditions described above and analyzed by SDS PAGE. To identify the *in vivo* S2056 DNA-PKcs phosphorylation site, 10 L of HeLa 25 S3 cells were irradiated with 25 Gy of ionizing radiation. Nuclear extracts made from the irradiated cells and immunoprecipitated, according to the method described in Example 3, with the 25-4 monoclonal antibody to DNA-PKcs (NeoMarkers, Lab Vision, Fremont, CA) and analyzed by SDS PAGE. All chemicals in this analysis were obtained from Fisher Scientific (Pittsburgh, PA).

[074] The coomassie blue-stained DNA-PKcs bands were excised from the gel and destained with 50 mM NH₄CO₃ in 50% methanol. Once destained, the gel slices were fixed overnight with 10% acetic acid and 50% methanol. The gel slices were then swelled with water for 2 hr and ground to a fine powder in 10 μ L of 50 mM NH₄HCO₃. Trypsin (Roche Diagnostics, Alameda, CA) was added and the samples were incubated at 37°C for 90 min.

The digested peptides were extracted from the gel with acetonitrile and concentrated by centrifugation with SpeedVac. A portion of the dried peptides was redissolved in 50 mM NH₄CO₃ for digestion with Asp-N protease (Roche Diagnostics, Alameda, CA) at 37°C for 90 min and dried. The dried tryptic and tryptic-Asp N peptides were dissolved in 10µL of 5% acetonitrile for further processing. A portion of the sample was treated with calf intestine phosphatase (CIP) (New England Biolabs, Beverly, MA) in 50 mM NH₄CO₃ at 37°C for 90 min and dried by centrifugation in a SpeedVac. The dried peptides were redissolved in 2 µL of 50% acetonitrile for MALDI-TOF mass spectrometry.

[075] The CIP-treated and untreated peptides were analyzed in a Voyager DE MALDI-TOF system from Perspective Biosystems. Most of the peaks in the spectrum of the tryptic digest could be easily assigned to unique peptides predicted from the protein sequence and to peptides formed by autolysis of trypsin. Peaks that could not be accounted for in this way were candidates for modified peptides, and those peptides having observed masses that were 80 Da (or multiples of 80 Da) higher than that calculated for a predicted tryptic peptide were tentatively assigned as phosphopeptides. This assignment was confirmed by the absence of these peaks from the MALDI/TOF spectrum of the same peptide mixture after treatment with CIP and the appearance of new peaks that are 80 Da (or multiples of 80 Da) lower in mass. Once the phosphorylated peptide was identified, it was then analyzed on an electrospray ion trap mass spectrometer (LCQ, Finnigan MAT, San Jose, CA) coupled online with a capillary HPLC (Magic 2002, Michrom BioResources, Auburn, CA) to identify the phosphorylation sites in the phosphorylated peptides.

[076] Referring now to Fig. 1, there is shown the mass spectra of one of the tryptic fragments. Fig. 1 is a mass spectra of sequencing of the *in vitro* phosphorylated DNA-PKcs peptide that was first identified by MALDI-TOF mass spectrometry. The plot shows a plot of relative intensity *vs* the mass-to-charge ratio (m/z) of the phosphorylated peptide having the sequence (shown in the Figure) from 2599 to 2619. Assignment of all the mass spectra peaks unequivocally identify T2609 as the site of phosphorylation. Thus, T2609 was unambiguously identified as a major site of autophosphorylation (Fig. 1).

[077] Referring now to Fig. 2, a second major *in vitro* and *in vivo* autophosphorylation site of DNA-PKcs, S2056, was identified by immunoprecipitating DNA-PKcs from nuclear extracts prepared from irradiated HeLa cells and analyzing by mass spectrometry (Fig. 2). DNA-PKcs from irradiated HeLa cells was purified by immunoprecipitation and digested with Asp-N protease. The peptide mixture was treated or mock treated with alkaline phosphatase and analyzed by MALD-TOF mass spectrometry.

Shown in Fig. 2 is the mass spectra of phosphatase-treated (bottom trace) and the mock treated (top trace) peptide mixture. The loss of the peak with the m/z of 3511 with phosphatase treatment, and the presence of the peak corresponding to the unphosphorylated peptide (m/z of 3433) allowed the inventors to positively assign a phosphorylation site to a sequence of DNA-Pkcs between amino acids 2044-2072. This peptide was then sequenced by tandem mass spectrometry (as in Fig 1) to unequivocally identify S2056 as the site of phosphorylation.

5 [078] Mass spectrometry identified the following phosphopeptide sequence, SEQ ID NO: 5, DFSTGVQSYSYSQDPRPATGRFRRREQR, which corresponds to amino acids 10 2044 to 2072 of DNA-PKcs (S2056 is underlined).

EXAMPLE 2

DNA-PKcs Fragments and GST Fusion Proteins Containing Autophosphorylated

Sites

15 [079] 20 bp oligomer primers were designed and ordered from Operon (Alameda, CA) using SEQ ID NO: 4 (the nucleotide sequence of DNA-PKcs, GenBank Accession Number: P78527) to created primers to amplify cDNA sequence that encodes the phosphorylation sites, T2609 and S2056. Designed DNA-PKcs cDNA fragments that cover the phosphorylation sites in DNA-PKcs found by mass spectrometry were PCR amplified 20 from the full-length DNA-PKcs cDNA (isolated and described by several of the inventors in Kurimasa et al., *Mol Cell Biol* 19: 3877-3884, 1999) using the custom designed PCR primers under normal PCR thermal cycling conditions. The reactions were carried out using *pfu* DNA polymerase (Stratagene, La Jolla, CA) and GeneAmp 9600 thermocycler (Perkin Elmer). The amplified cDNA fragments were cloned in frame into GEX-KG vector (Guan & Dixon 1991 *Analytical Biochem.* 192:262-67) for fusion between domains of DNA-PKcs and GST.

25 [080] These clones were made to express the following residues of DNA-PKcs from the indicated corresponding cloned cDNA sequence: 1879-2182 cDNA (SEQ ID NO: 18), 1879-2267 cDNA (SEQ ID NO: 19), 2261-2700 cDNA (SEQ ID NO: 21), 2275-2702 cDNA 30 (SEQ ID NO: 23), 2429-2702 cDNA (SEQ ID NO: 24), 2561-2700 cDNA (SEQ ID NO: 25), and 2600-2702 cDNA (SEQ ID NO: 26).

[081] Peptide fragments were expressed by the clones which encode the following peptides and correspond to the following residues of DNA-PKcs: 1879-2182 (SEQ ID NO:

6), 1879-2267 (SEQ ID NO: 7), 1879-2700 (SEQ ID NO: 8), 2261-2700 (SEQ ID NO: 9),
2500-2702 (SEQ ID NO: 10), 2275-2702 (SEQ ID NO: 11), 2429-2702 (SEQ ID NO: 12),
2561-2700 (SEQ ID NO: 13), and 2600-2702 (SEQ ID NO: 14).

[082] Several of these fragments were also made into glutathione-S-transferase
5 (GST) fusion proteins. The PCR'd fragments were cut randomly and then fused with the
GST protein using the commercially available GST fusion vector (Amersham Biosciences,
Piscataway, NJ).

EXAMPLE 3

Preparation of Cellular Nuclear Extracts from Cells

[083] The preparation of nuclear extract from HeLa cells for the Examples that
follow were made as generally described by Lees-Miller et al., *Mol Cell Biol* 10: 6472-6481,
1990 and is herein described. The cells were washed twice with cold PBS, collected, and
15 spun at 2000g for 5 min. The cell pellet is washed once with 5 ml LSB and spun again. The
pellet is resuspended in 1ml LSB and transfer to a centrifuge tube. (LSB (low salt): 10 mM
Hepes pH7.5, 25 mM KCl, 10 mM NaCl. 1mM MgCl₂, 0.1mM EDTA).

[084] After spinning down again, the volume of the cell pellet is estimated, then
resuspended in 1x Pack cell volume (PCV) of LSB (with 50 mM NaF, 1mM DTT, 0.5 mM
PMSF, and other protease inhibitors), set in ice 5 min, and freezed in liquid N₂. Thaw, and
20 spin immediately at 10,000g for 10 min. Dispose of Supernatant (S10, cytosol fraction).

[085] The pellet is again resuspended in 1x pack nuclear volume (PNV) of LSB with
0.5M NaCl and 10 mM MgCl₂ (500 mM NaCl, 10 mM MgCl₂, 50 mM NaF , 1mM DTT, 0.5
mM PMSF), set in ice for 10 min. For this step, LSB (0.5 M salt): 10 mM Hepes pH7.5, 25
mM KCl, 500 mM NaCl. 10mM MgCl₂, 0.1mM EDTA. The pellet is spun down at 40,000g
25 for 20 min, supernatant (P10 nuclear fraction). The collected P10 nuclear extract is mixed
1:1 with 2X Laemmli buffer (80mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 0.1%BPB),
then the sample is boiled at 100 °C for 3 min.

EXAMPLE 4

SDS Gels and Western Blots for DNA-PKcs

[086] Western blotting for the following Examples was performed as generally
described by Chan et al., *Biochem Cell Biol* 74: 67-73, 1996 and herein described.

[087] **Preparation of 8% low bisacrylamide gels.** Resolution gel mix (10 ml): 3ml
30% acrylamide, 0.4ml 2% bisacrylamide , 2ml 1M Tris-HCl pH8.8 , 3ml water , 100ul 10%

SDS, 100ul 10% APS, 8ul TEMED, allow to polymerize for at least 90 min. Stacking gel mix (5 ml): 3.4 ml water, 0.83 ml 30% acrylamide, 0.63 ml 1M Tris pH6.8, 50ul 10% SDS, 50ul 10% APS, 5ul TEMED, allow to polymerize for at least 30 min.

5 [088] **Gel Running.** Load the samples and run at 100V 1.5 to 2 hrs until BPB dye runs off. The electrophoresis running buffer is made as followed (per liter): 6 g Tris base, 28.8 g Glycine, 1 g SDS. Do not pH.

10 [089] **Transfer.** Remove gel from glass plates and place in 50ml electroblot, gently rock for 5-15 min. Electroblot (per liter): 5.8g Tris base, 2.93g glucine, 0.38 g SDS, 100ml methanol. For each gel to be blotted, prepare 2 squares of 3 mm filter paper cut to size of gel and place them in electroblot. Cut 1 square piece of nitrocellulose or PVDF membrane about the same size.

15 [090] Wet the PVDF membrane with Methanol, and equilibrate in electroblot for 5 min before use. For nitrocellulose, place directly in electroblot. Submerge blotting cassette and Scotchbrite pads in electroblot, assemble as follows: towards the black side of the cassette, scotchbrite (sponge), 3 mm filter paper, gel, nitrocellulose membrane, 3 mm filter paper, and then scotchbrite. Make sure that no air bubbles are trapped between the gel and the nitrocellulose membrane by smoothing out with gloved finger or rolling with a glass rod. Place assembly in transfer chamber with black side to black side; add the frozen cooling pack and fill to top with electroblot. Transfer at 100V (~250mA) for 1 hour on ice bath or 15V 20 overnight at RT with gentle stirring of the electroblot.

25 [091] **Western Blot.** Place membrane in block solution (5% none fat milk powder in TTBS) for at least 60 min. TTBS: 10 mM Tris pH 8.0, 150 mM NaCl, 0.1% TWEEN-20.

[092] Incubate the blot with primary antibody for 1 to 2 hrs at RT, 1: 1000 dilution of purified DNA-PKcs antibodies in block solution. Wash blot with TTBS for 10 min, three times. Incubate blot with secondary antibody for 30 min at RT, 1: 5000 dilution of goat anti-rabbit HRP conjugate (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) in TTBS.

30 [093] Wash blot with TTBS for 10 min, three times. Make up ECL solutions (Amersham Biosciences, Piscataway, NJ): 1ml of each A and B is sufficient for a blot. Immerse blot in ECL solution for 1 minute, remove from ECL solution, place in a sandwich of plastic wrap, expose blot to film in dark room for various times (5 sec to 10 min), and develop film.

EXAMPLE 5

Cellular Radiation Sensitivity and Defective DSB Repair in Cells Having T2609A and S2056A Mutant Proteins

[094] To investigate the biological significance of the T2609 and S2056 phosphorylation in relation to DNA repair, wild-type or mutant DNA-PKcs were tested for 5 DNA DSB repair, and radiation survival. DNA-PKcs expression constructs were made and transfected into the DNA-PKcs-defective V3 CHO cell line (Kurimasa et al., *J Immunol.* 2000 Oct 1;165(7):3883-9). Stable V3 cell lines that were expressing wild-type DNA-PKcs (V3-F18), T2609A DNA-PKcs mutant proteins (V3-T2609A), S2056A DNA-PKcs mutant proteins (V3-S2056A) and S2056A/ T2609A DNA-PKcs double-mutant proteins (V3-10 S2056A/T2609A) were isolated and evaluated for DNA-PKcs protein expression levels, radiation sensitivity and DNA repair defects. The radiation sensitivity of these cell lines was examined by assaying for their colony forming ability after IR.

[095] The following was used to carry out site-directed mutagenesis and isolation of 15 the mutant cell lines. The creation of the T2609A mutant (V3-T2609A) is herein described. The S2056A DNA-PKcs mutant (V3-S2056A) and S2056A/T2609A DNA-PKcs double-mutant (V3-S2056A/T2609A) were generated using the same methods but different primers.

[096] First, a 3kb Hind III fragment of DNA-PKcs cDNA covering T2609 was used 20 as the template for generating the T2609A mutation of DNA-PKcs cDNA. Site-directed mutagenesis was performed using the Quik Change site-directed mutagenesis kit (Stratagene, La Jolla, CA) and the forward (tccgatgttgtggaggaccaggcctcccagggc) (SEQ ID NO: 27) and reverse (gccctggaggcctggcctccacaaacatcgga) (SEQ ID NO: 28) primers. The mutated DNA-PKcs cDNA fragment was assembled back into the full length DNA-PKcs cDNA as described in Kurimasa et al., *Mol Cell Biol* 19: 3877-3884, 1999. Cells were maintained at 37°C in a humidified atmosphere of 5% CO₂ in air by using alpha-MEM 25 medium supplemented with 10% fetal calf serum, 100 U of penicillin per ml, and 100 µg of streptomycin per ml. Transfection of the DNA-PKcs expression plasmid was performed with a calcium phosphate transfection system (Catalog no. 18306-019; Gibco-BRL, Gaithersburg, MD). For each 10⁶ cells in a 100-mm tissue culture dish, 10 µg of the DNA-PKcs expression vector and 10 µg of the pSV2neo or pPur plasmid were transfected.

[097] T2609A DNA-PKcs expression plasmid together with pSV2neo plasmid were 30 transfected into the V3 cell line. Forty-eight hours after transfection, cells were replated on selection medium containing 400 µg/mL of G418 for 10 days. After 7 to 21 days of selection, individual colonies were isolated and further cultured.

[098] Colony formation and FAR (Fraction of Activity Released) assays were performed as previously described (Kurimasa et al., *Mol Cell Biol* 19: 3877-3884, 1999).

[099] Radiation survival assays generated survival curves for each cell line. These survival curves were obtained by measuring the colony-forming abilities of irradiated cell populations. Three hundred cells were plated on 60-mm plastic petri dishes and irradiated with ^{137}Cs γ rays at 2 h after plating at a rate of 2.2 Gy/min to achieve a cumulative dose of 1, 2, 3, or 5 Gy. After 7 to 14 days, cells were fixed and stained with 1% crystal violet in a 70% ethanol solution, colonies containing more than 20 cells were scored, and the mean value for triplicate culture dishes was determined. Cell survival was normalized to plating efficiency of untreated controls for each cell type.

[0100] Referring now to Fig. 3A, nuclear extracts were prepared as described in Example 3 from V3 cells transfected with vector alone (V3-JM), full length wild-type DNA-PKcs (V3-WT) or DNA-PKcs containing the T2609A point mutant (V3-T2609A1) were analyzed for DNA-PKcs protein expression levels (top panel). Nuclear extracts (P10) were prepared as described in Example 3. 20-60 μg of each sample was analyzed by western blotting as described in Example 4. For analysis of the V3 cell lines, the DNA-cellulose pull-down method of Finnie et al. (*Proc Natl Acad Sci U S A* 92: 320-324, 1995) was used to first concentrate DNA-PKcs onto the cellulose and then subjected to SDS-PAGE for western blotting. Hamster Werner proteins were analyzed to demonstrate equal sample loading (bottom panel). DNA-PKcs protein levels in V3 (lane 1) is undetectable due to low abundance of DNA-PKcs RNA, whereas, V3-WT (lane 3) and V3-T2609A (lane 4) showed similar levels of protein expression (Fig. 3A, top panel). On the bottom, the expression of *wrn* (another DNA repair protein) was determined to show the equal loading of the samples.

[0101] Complementation of human DNA-PKcs in V3 cells restored radioresistance resulting in survival that is comparable to wild-type CHO cells (Fig. 3B). In Fig. 3B, the V3 cells complemented with the S2056A mutation DNA-PKcs (V3-S2056A), T2609A mutation DNA-PKcs (V3-T2609A) and S2056A/T2609A double mutation DNA-PKcs (V3-S2056A/T2609A) showed a radiation sensitivity phenotype that was more severe than the wild type. Although expression of the S2056A and T2609A mutant proteins improved the survival of the V3 cell line, the survival rates were significantly lower than what was observed for V3-WT. The dose of IR required for 10% survival of the V3-JM, V3-S2056A, V3-T2609A, V3-S2056A/T2609A, and V3-WT cell lines was 1.2 Gy, 1.9 Gy, 2.4 Gy, 2.1 Gy, and 5 Gy, respectively (Fig. 3B). Thus, the D_{10} value is approximately four-fold higher

for V3-WT compared to the V3-JM non-complemented cells (that is 5 Gy/1.2 Gy), whereas resistance at the 10% survival level was increased by only two-fold in the V3-T2609A1 cells (5 Gy/2.4 Gy). However, the resistance at the 10% survival level is increased by about 2.5 times in the cell lines containing the S2056A mutation, thus showing the significance of phosphorylation of the S2056 site in radioresistance. At around 4 Gy, both the S2056Amutant and the double mutant drop below 1.0% survival rate, showing a greater radiosensitivity is caused by mutating the S2056 site than the T2609 site alone. At a dosage of 5 Gy, the T2609A mutant survival rate was less than 1% while the wild type cells having functional DNA-PKcs showed a 10% or greater survival rate. Therefore, phosphorylation of T2609 and S2056 are shown to be important for cell viability in response to ionizing radiation (IR).

[0102] The presence of additional DNA-PKcs phosphorylation sites may explain why the V3-T2609A1 cells showed only a roughly two-fold increase in radiation sensitivity (at 10 Gy, Fig. 3B). In response to DNA damage, phosphorylation of multiple sites may be required for proper DNA-PK function, and thus explaining why mutation of T2609 produced only a two-fold increase in radiation sensitivity, but the mutation of S2056 produced a greater increase to radiation sensitivity.

[0103] In Fig. 3C, T2609A mutation compromises DSB repair as shown by the FAR (fraction of activity released) Assay which is a DSB rejoicing assay. The FAR Assay is used to analyze the mobility of genomic DNA in the polyacrylamide gel electrophoresis (PAGE) and to measure the presence of DNA DSBs. The FAR assay uses pulsed field gel electrophoresis to indirectly measure the intactness of DNA in cells after gentle lysis in agarose plugs by quantifying the amount of DNA released from the wells immediately after IR exposure as a function of dose or after a period of incubation to allow repair after a given dose (Story et al., *Int J Radiat Biol* 65: 523-528, 1994).

[0104] The V3-JM, V3-WT, V3-T2609A1 cell lines and the parental CHO cell line (AA8) were irradiated at the indicated dose and analyzed for the presence of DSBs by the FAR assay. DNA DSB repair activity following exposure to ionizing radiation was measured by two different methods: (i) rejoicing kinetics, plotted as a function of time course after irradiation; and (ii) measure of residual DNA DSB lesions following exposure and recovery to three doses (0, 20, and 40 Gy) of ^{137}Cs γ rays. Exposures consisted of a dose rate of about 4 Gy/min on ice. Immediately following irradiation, the cold medium was replaced with medium that had been warmed to 37°C and the cells were placed in a 37°C tissue culture incubator for 4 h to allow for DNA DSB repair. The cells were then trypsinized on ice,

washed, suspended in agarose plugs, lysed, and electrophoresed. Residual DNA DSB lesions were determined by CHEF pulsed-field gel electrophoresis combined with a storage phosphorimaging system. Rejoined lesions were defined as the fraction of DNA that had regained sizes large enough to prevent migration during electrophoresis (DNA retained) and measured by comparing the intensity of fluorescence of the DNA fraction retained in the agarose well.

[0105] Referring now to Fig. 3C, there is a graph showing the results of the FAR assay utilized to evaluate the ability of each of the three cell lines to rejoin DSBs induced by IR. The graph plots the percentage of DNA retained in the well (which shows DSB rejoining capacity) versus total radiation dosage. The V3-WT and the parental AA8 CHO cell lines showed comparable DSB rejoining capacities (Fig. 3C, open (80% retained) and closed circles (85% retained), respectively) and . In contrast, the V3-JM and the V3-T2609A cells were significantly more defective in the rejoining of DNA DSBs at 4 hrs after irradiation (only 70% of DNA retained in well), consistent with previous observations (Kurimasa et al., 10 *Mol Cell Biol* 19: 3877-3884, 1999) and with the hypothesis that DNA-PKcs plays an important role in repair of DSBs. Together, these results show that phosphorylation of DNA-PKcs at T2609 is important for rejoining of DSBs and for cell survival in response to DNA damage caused by IR.

20 EXAMPLE 6

Generation and Specificity of Phosphospecific Polyclonal Antibodies to pT2609 Site and pS2056 Site

[0106] To study the *in vivo* phosphorylation status of DNA-PKcs at T2609 and S2056, phosphospecific antibodies were generated. The phosphospecific antibodies, 25 pT2609Ab, recognizes phosphorylated T2609, and pS2056Ab recognizes phosphorylated S2056. pT2609 polyclonal antibodies were prepared by immunizing New Zealand white rabbits with a KLH-conjugated phosphopeptide, N'-TPMFVET[PO³]QASQGT-C' (SEQ ID NO: 1). pS2056 polyclonal antibodies were prepared by immunizing New Zealand white rabbits with KLH-conjugated phosphopeptide, N'-QSYSYSS[PO³]QDPRPAC-C' (SEQ ID 30 NO: 2).

[0107] **KLH-Conjugated Phosphopeptide.** To create the KLH-conjugated phosphopeptide (SEQ ID NO: 1 and 2), the phosphopeptide was made by conventional oligonucleotide synthesis means by AgBio, Inc. (Fremont, CA). 10 mg of the phosphopeptide was dissolved in 0.05 mL DMSO first, then 1 mL PBS (PBS: 0.1 Phosphate

buffer + 0.15 M NaCl, pH 7.3) was added and mixed. Activated KLH (10 mg Soluble keyhole limpet hemocyanin) (Calbiochem #374817, EMD Biosciences, San Diego, CA) was mixed with the dissolved peptide and the mixture was incubated at 4 °C with gentle rotation for overnight or room temperature (RT) for 3 hours. At the end of the first incubation, 10 mg 5 cysteine (L-cysteine HCl, Sigma, St. Louis. MO) in 2 mL PBS was added to the mixture, then vortexed briefly.

[0108] The phosphopeptides were conjugated to KLH by cross-linker Sulfo-SMCC (Pierce Biotechnology, Inc., Rockford, IL) which forms a disulfate bridge with the cysteine residues placed at the C' terminal of the synthesized peptides and cysteine residues on KLH. 10 The mixture was then incubated with rotation at RT for 2 hours to block unreacted SMCC. Dialysis against 2L PBS was done with at least 2 buffer changes. Dialysis may proceed overnight. In place of dialysis, a SEPHADEX G-25 column (Amersham Biosciences, Piscataway, NJ) may be used again to desalting.

[0109] The peptide/KLH conjugate solution was collected in dialysis bag or in 15 fractions (in case of G-25 gel) and 18 mg NaCl to each mL of the solution was dissolved to give the solution additional 0.3 M NaCl. The solution was centrifuged if particulates or precipitates observed. The protein concentration of the clear conjugate solution was measured by using $A_{280\text{nm}}$ and a coefficient $1.4 = 1 \text{ mg/mL}$. The conjugate solution was then diluted to 1 mg/mL and aliquoted 1 mL of the peptide-KLH conjugate solution into tubes. 20 Each tube contained 1 mg of the conjugate and was sufficient for one immunization dose for two rabbits. The tubes were stored at -20 °C until use.

[0110] The polyclonal antibodies were made by immunizing New Zealand white rabbits with the above KLH-conjugated phosphopeptide, (SEQ ID NO: 1 and 2) using standard methods well known in the art by AgBio, Inc (Fremont, CA). Crude rabbit serum 25 was collected from the immunized rabbits. The KLH-conjugated phosphopeptides were then mixed with adjuvant and were injected into a rabbit through intradermal injection to elicit immunogenic response. After repeated injection to boost the immunogenic response, samples of serum were collected and tested by ELISA assay (to determine the titer of the antibodies) until the titer reached to the peak. The antibodies were then harvested.

[0111] The phosphospecific antibodies were affinity purified through a phosphopeptide-conjugated Sepharose CL-4B column. SEQ ID NO: 1 was made as an 30 unphosphorylated peptide, N'-PMFVETQASQGTC-C' which corresponds to the T2609 site

unphosphorylated. SEQ ID NO: 2 was made as an unphosphorylated peptide, N'-QSY SYSSQDPRPAC-C', to correspond to the S2056 site unphosphorylated.

[0112] The following protocol was used to affinity purify the pT2609 and pS2056 rabbit polyclonal antibodies. Two columns are needed. One column uses an unphosphorylated version of the phosphopeptides used to immunize the rabbits. A second column uses the phosphopeptides. Eluted IgGs are passed through the first unphosphorylated peptide column to deplete any IgGs that are not specific to pT2609 or pS2056 and then the flow-through is then passed through the second phosphopeptide column to affinity purify the polyclonal antibodies specific for pT2609 and pS2056.

[0113] To prepare the columns, dissolve the appropriate peptide (1 mg/per ml) in coupling buffer: 50 mM Tris pH 8.5, 5 mM EDTA. Pack 5 ml SulfoLink Coupling Gel (Pierce Biotechnology, Rockford, IL) in 10 ml disposable polystyrene column (Pierce Biotechnology), equilibrate the column with 6 column volumes of coupling buffer. Place the bottom cap to the column, and add 5 ml peptide solution (5 mg) to the column. Place top cap, and mix the column at RT for 15 minutes with gentle rotation. Set for 30 minutes without mixing. Drain buffer, wash column with 3 column volumes of coupling buffer. Place the bottom cap to the column, and add 5 ml 50 mM cysteine to the column. Place top cap, and mix the column at RT for 15 minutes with gentle rotation. Set for 30 minutes without mixing. Drain buffer, wash column with 16 column volumes of 1 M NaCl.

[0114] For affinity purification, wash both non-phospho and phosphospecific peptide columns with 5 column volumes of PBS. Load 15 to 30 ml crude rabbit serum onto non-phosphopeptide column in RT. Collect flow-through. This step is to remove none specific antibodies. Load the flow-through onto phosphospecific peptide column with PBS. Wash with 10 column volumes of PBS with 0.5 M NaCl. Elute with 3 column volumes of 0.1 M glycine pH2.5, collect 1 ml fraction and neutralize the pH with 50 μ l 1M Tris pH 8.0, and check protein concentration by Bradford assay (Bio-Rad, Richmond, CA) and freeze in -20°C.

[0115] In Fig. 4A, GST fusion proteins, having fragments spanning amino acids 2500-2700 (SEQ ID NO: 10) fused to GST, were made according to Example 2. The fragments contained either the wild-type DNA-PKcs sequence or the T2609A point mutation. The GST fusion proteins were *in vitro* phosphorylated with purified DNA-PK as described in Example 2 and analyzed by Western blot according to Example 5. The wild-type DNA-PKcs sequence and the T2609A point mutation were probed with the pT2609pAb (top panel) and anti-GST (bottom panel) to show equal loading. The lack of any signal detected for T2609A

by the pT2609pAb of the invention in the Western blot shows that T2609 in DNA-PKcs is phosphorylated and that the pT2609pAb is specific for the phosphorylated T2609 site.

[0116] Referring now to Fig. 4B, the Western blot shows that pT2609pAb is specific to phosphorylated T2609 and does not recognize unphosphorylated DNA-PKcs. In Fig. 4B, 5 affinity-purified pT2609 polyclonal antibody was used in immunoblotting with mock or autophosphorylated DNA-PKcs, lanes 1 and 2, respectively, and in the presence of excess unphosphorylated DNA-PKcs at the indicated molar excess ratios. Immunoblotting with unphosphorylated DNA-PKcs at 100 fold molar excess (relative to the phosphorylated DNA-PKcs) did not produce a detectable signal. Western blotting with pT2609pAb (top panel) 10 and 25-4 DNA-PKcs monoclonal antibody (bottom panel) with mock or autophosphorylated DNA-PKcs (lanes 1 and 2, respectively) and with purified, unphosphorylated DNA-PKcs (lanes 3 to 9) at the indicated molar ratios relative to the amount of protein in lanes 1 and 2.

[0117] Referring now to Fig. 4C, a similar experiment shows that affinity purified pS2056Ab is specific to phosphorylated S2056. V3 (DNA-PKcs deficient CHO cells) 15 complemented with either wild type human DNA-PKcs cDNA (V3-F18) or kinase dead mutant (V3-KA4) were subjected to mock or 10 Gy of ionizing radiation. DNA-PKcs protein was immunoprecipitated from nuclear extracts by 25-4 DNA-PKcs monoclonal antibody, and western blotted with the generated pS2056 rabbit polyclonal antibody (bottom panel). The blot was stripped and reprobed with the 25-4 DNA-PKcs monoclonal antibody (top panel). 20 S2056 phosphorylation was diminished in V3-KA4 (kinase dead mutant) as compared to that of V3-F18 (wild type DNA-PKcs) indicating that DNA-PKcs autophosphorylation is responsible for IR-induced S2056 phosphorylation.

EXAMPLE 7

Localization of pT2609 Antibody to Site of DNA Double-Strand Breaks

[0118] In response to DNA damage, many DNA repair proteins form nuclear foci, presumably, the site of the DNA DSBs (Rogakou, *J Cell Biol* 1999 Sep 6; 146(5):905-16; Maser et al., *Mol Cell Biol*. 1997 Oct; 17(10):6087-96). To determine the status of DNA-PKcs in response to DNA damage, DNA-PKcs was examined by immunofluorescence 30 microscopy. Immunostaining with a monoclonal antibody to DNA-PKcs produced strong signal throughout the nucleus, in both unirradiated and irradiated cells (not shown).

[0119] Fluorescent immunostaining showed that pT2609pAb produce foci only in irradiated but not unirradiated primary human skin fibroblasts (HSF). Immunofluorescence was performed as previously described in (Burma et al. 2001, *J Biol Chem* 276: 42462-

42467). In contrast, immunostaining with 25-4 (a commercial monoclonal antibody to DNA-PKcs from Neomarkers, Lab Vision Corp, Fremont, CA) produced strong signal throughout the nucleus, in both unirradiated and irradiated HSFs, because DNA-PKcs is a very abundant nuclear protein.

5 [0120] Because DNA-PKcs is a very abundant nuclear protein, it is not possible to distinguish any foci in response to DNA damage with the monoclonal antibody. However, with the pT2609 polyclonal antibody, foci can be clearly detected in response to IR treatment. The number and size of foci varied with the dose of IR and reaches a maximum with 10 Gy (data not shown). In addition, the kinetics of the pT2609pAb foci formation is similar to
10 what was observed with the time-course western results in Fig. 5B.

[0121] To further confirm the localization of T2609 phosphorylation at DSB sites, we examined the colocalization of rabbit pT2609 polyclonal antibody foci with the p53 binding protein (53BP1) which has been previously shown to bind to the site of DNA DSBs (Rappold et al., *J Cell Biol.*, Apr 30;153(3):613-20 2001). Co-immunostaining with a 53BP1
15 monoclonal antibody (Rappold et al., *J Cell Biol.*, Apr 30;153(3):613-20 2001) and the pT2609Ab in unirradiated HSF cells did not produce any discernable foci above the background signal of the nucleus. 53BP1 monoclonal antibody was provide by Dr. Junjie Chen (Mayo Clinic, Rochester, MN). However, cells that were irradiated resulted in very discrete 53BP1 and pT2609pAb foci. Moreover, the 53BP1 and pT2609pAb foci co-
20 localized with each other. Thus by virtue of co-localization with 53BP1 foci in response to DNA damage, it was demonstrated that the pT2609pAb binds and becomes activated at the site of DNA DSB *in vivo*.

EXAMPLE 8

25 T2609 is Phosphorylated in Response to Irradiation *in vivo*.

[0122] Referring now to Fig. 5A, 50 µg of HeLa nuclear extracts made from unirradiated (lane 3) or cells irradiated with 25 Gy and harvested after a 30 min recovery period, were analyzed by western blotting with pT2609pAb (upper panel) or 25-4 monoclonal antibody (bottom panel). As shown in Fig. 5A, phosphorylation of T2609 is
30 DNA damage inducible and was detected as early as 10 minutes and reached a maximum at approximately 30 minutes after treatment. T2609 is phosphorylated up to 4 hours after IR treatment detectable, after which the phosphorylation of T2609 is not detectable (Fig. 5A). Purified DNA-PKcs was mock (lane 1, control) or autophosphorylated (lane 2) and analyzed by western blotting using the pT2609 polyclonal antibody of the invention. HeLa cells were

either mock treated or irradiated with 10 Gy and allowed to recover for the indicated times. Nuclear extracts were western blotted with pT2609pAb (top panel) and then blots were stripped and reprobed with the 25-4 DNA-PKcs monoclonal antibody (Neomarkers, Lab Vision Corp, Fremont, CA) (bottom panel). Since phosphorylation of T2609 can be detected 5 as early as 10 minutes after IR, this suggests that phosphorylation of DNA-PKcs is an early event in response to DNA damage and is consistent with the hypothesis that DNA-PK is required for the early and rapid phase of the "biphasic" model of DSB repair. This biphasic model was previously described in DiBiase et al., *Cancer Res* 2000 Mar 1;60(5):1245-53.

[0123] Phosphorylation of T2609 is also dose dependent, and can be induced with 2 Gy of IR and reaches a maximum or saturation with 10 Gy of IR. As shown in Fig.5B, HeLa 10 cells were irradiated with the indicated dose of IR and allowed to recover for 30 min. Nuclear extracts were first analyzed by western blot with pT2609pAb (top panel) and then with 25-4 monoclonal to show equal loading (bottom panel). Since phosphorylation of T2609 can be observed with a dose as low as 2 Gy, these results suggest that phosphorylation 15 of DNA-PKcs is very sensitive to the presence of DSBs in the genome. The inventors have also observed the same phosphorylation of T2609 in response to IR in a lymphoblastoid cell line (Jurkat), a glioma cell line (M059K) and in primary human fibroblasts (data not shown), and thus this event appears to be a general phenomenon that is not cell-type specific.

[0124] Phosphorylation at T2609 in response to DNA damage was further confirmed 20 by immunoprecipitation with the pT2609pAb. As shown in Fig. 5C, pT2609 polyclonal antibody was used to immunoprecipitate DNA-PKcs from 500 μ g of unirradiated HeLa nuclear extract (lane 1) or extracts made from HeLa cells irradiated with 25 Gy and harvested after 30 min recovery period. DNA-PKcs was immunoprecipitated with the pT2609pAb only 25 in the nuclear extracts prepared from irradiated cells but not from that of untreated cells, thus showing that the pT2609pAb is specific for phosphorylated DNA-PKcs.

[0125] In Fig. 5D, phosphorylation of T2609 in response to DNA damage can be inhibited with wortmannin treatment and is inducible in A-T cells indicating that DNA-PKcs autophosphorylation is responsible for T2609 phosphorylation *in vivo*. The activity of PI-3 kinase family members, including DNA damage responsible DNA-PK and ATM, are 30 sensitive to low dose of wortmannin (Sarkaria et al., *Cancer Res*. 1998 Oct 1;58(19):4375-82). Since phosphorylation of T2609 is through an autophosphorylation mechanism, then one would expect phosphorylation to be sensitive to the effects of wortmannin. Treatment of

HeLa cells with 20 µm wortmannin, resulted in a decrease in the detectable levels of phosphorylated T2609 (Fig. 5D).

[0126] To determine whether the ATM (ataxia-telangiectasia-mutated) kinase may phosphorylate T2609 in response to IR, ATM deficient lymphoblastoid cell line (L3) and 5 ATM positive cell line (BT) were treated with ionizing radiation and probed with pT2609pAb. In response to IR, phosphorylation of T2609 was observed in both the ATM wild-type (BT) and mutant (L3) cell lines, thus phosphorylation of DNA-PKcs at T2609 is ATM-independent.

10 EXAMPLE 9

Phosphorylation of S2056 *in vivo*

[0127] The observed S2056 phosphorylation *in vivo* data is similar to that of T2609. The experiments described in the previous Example were performed using p2056 polyclonal antibody (pS2056pAb) to observe the phosphorylation of S2056 *in vivo*. Referring now to 15 Fig. 6A, phosphorylation of S2056 induced by irradiation *in vivo* was observed in HeLa cells (lane 2), wild type fibroblasts (lane 4), as well as ATM (ataxia-telangiectasia-mutated) deficient fibroblasts (lanes 6 and 7). S2056 phosphorylation in response to IR in ATM deficient fibroblasts also indicates that DNA-PKcs autophosphorylation is likely responsible for S2056 phosphorylation *in vivo*. The gel in Fig. 6A shows that the pS2056pAb detects 20 phosphorylated DNA-PKcs only in irradiated cells (lanes 2, 4, 6 and 7) but not unirradiated cells (lanes 1, 3, 5 and 8). In addition, fluorescent immunostaining with pS2056 antibody show that pS2056pAb detects only phosphorylated DNA-PKcs and is localized at DSB sites (nuclear foci) only in irradiated but not unirradiated cells (data not shown).

[0128] Referring now to Fig. 6B, a main difference between T2609 and S2056 phosphorylation is that prolonged phosphorylation of S2056 can be detected upon DNA damage. S2056 phosphorylation can be detected six to eight hours after IR whereas T2609 phosphorylation is diminished after about 4 hours indicating the phosphorylation at T2609 and S2056 may have overlapping and distinct functions.

30 EXAMPLE 10

Generating pT2609 and pS2056 Monoclonal Antibodies

[0129] Specific mouse monoclonal antibodies against pT2609 and pS2056 were prepared using immunogens disclosed herein. Protocols for immunization and construction

of hybridomes may be found in U.S. Pat. No. 4,455,296 to Hansen et al and U.S. Pat. No. 4,364,933 to Kong et al and are hereby incorporated by reference. The screening process, is as described in Example 6. The cell lines and monoclonal antibodies recognizing only the phosphopeptides but not non-phosphopeptides are selected. Therefore, there is no need of 5 affinity purification of Example 6 for the phospho specific mouse monoclonal antibodies. Monoclonal antibodies to phosphorylated T2609 (pT2609mAb) and phosphorylated S2056 (pS2056mAb) were generated according to the protocol herein described.

[0130] Female BALB/c mice were subcutaneously injected with 100 μ g/mouse into one spot with the phosphopeptide once a month for 4 months. The phosphopeptide was 10 added to incomplete Freund's adjuvant. Testbleeds from mice's tail were drawn once a month after sterilizing mice skin with 70% alcohol. After 4 months of immunization, mice were given a final booster injection 4 days before doing fusion. The phosphoprotein was injected without adjuvant. The polyclonal mouse serum was collected from the hearts. The mice were sacrificed and the spleens and NS-1 myeloma cells were harvested.

15 [0131] The fusion of the harvested mouse NS-1 cells and spleen cells (B lymphocyte cells) was carried out according to the following method. Prepare hypoxanthine-aminopterin-thymidine (HAT, Sigma) medium (300 ml 15% RPMI medium + HTA) two days before. Defrost NS-1 cells (ATCC, Manassas, VA) and cultured in 15% RPMI medium (Gibco BRL, Gaithersburg, MD) (with 15% Fetal Bovine Serum obtained from Hyclone (Logan, UT)).
20 Prewarm 2 ml 50% PEG, 5 and 15 ml RPMI, and 15% RPMI-HAT medium at 37°C.

[0132] Rinse the spleen in 5 mL RPMI in 60 mm petri dishes five times. Collect the spleen cells and put into 15 ml centrifuge tubes (4°C). Pass the spleen cells through 25-gauge needles three times and 21-gauge needles three times. Spin at 4°C, 1800 rpm, 5 minutes. Collect NS-1 cells (about 200 ml culture) and put into 50 ml centrifuge tubes.

25 [0133] Spin at 4°C, 1400 rpm, 5 minutes. Resuspend spleen cells with 5 ml RPMI medium and stand for 2 minutes. Transfer the supernatant of spleen cells into a new 50 ml tube and repeat spin at 4°C, 1400 rpm, 5 minutes and resuspend spleen cells with 5 ml RPMI medium and stand for 2 minutes. Re-suspend the NS-1 cells in 15 ml RPMI and transfer into one 50 ml tube. Spin NS-1 cells, resuspend pellets and spin, and then resuspend the pellets 30 with 20 ml RPMI medium. Spin spleen cells, 4°C, 1800 rpm, 5 min, resuspend the pellets with 4 ml RPMI medium. Count cell numbers in 2 μ L spleen cells in 88 μ l ammonium chloride (incubate 5 min, lysis RBC) and 10 μ l tryphan blue (before counting). Count number of cells in 5 μ l NS-1 cells, 40 μ l PBS and 5 μ l tryphan blue.

[0134] Keep some spleen (5×10^6) and NS-1 (1×10^6) cells as control. Transfer optimum amount of NS-1 cells into spleen cell tube. The optimum amount is 1:5 = NS-1 cells:Spleen cells. Spin at 4°C, 1800 rpm, 5 min and completely remove the supernatant. Drop by drop over 1 min period, add 1 ml pre-warmed 50% PEG with continually shaking the tube, shaking 30 sec, stand for 1 min (37°C). Drop by drop over 5 min period, add 5 ml RPMI medium to the fusion mixture while gently agitating (37°C). Immediately add 15 ml RPMI medium over a 1 min period. Incubate the fusion mixture in 37°C water bath for 5 min. Spin down the cell pellets at 25°C, 1800 rpm, 5 min. Re-suspend the cell pellets with 15% RPMI-HAT medium (1×10^6 spleen cells/ml). Use normal mouse splenocytes as feeder cells (seeding before cell fusion). Seed the cell suspension in 96 well plate (200 μ l/well), culture two weeks. Screen positive clones by dot blot assay.

[0135] The present examples, methods, procedures, treatments, specific compounds and sequences are meant to exemplify and illustrate the invention and should in no way be seen as limiting the scope of the invention. Any patents or publications mentioned in this specification are indicative of levels of those skilled in the art to which the patent pertains and are hereby incorporated by reference to the same extent as if each was specifically and individually incorporated by reference.

CLAIMS

What is claimed is:

- 5 1. An antibody which specifically binds to an epitope defined by at least a ten amino acid sequence from human DNA-PKcs, said sequence comprising:
a phosphorylated threonine at position T2609, wherein:
said antibody does not bind when T2609 is not phosphorylated.

- 10 2. The antibody of claim 1, wherein:
said antibody is a monoclonal antibody.

3. The antibody of claim 2, wherein:
said monoclonal antibody is a human monoclonal antibody

- 15 4. The antibody of claim 1, wherein:
said antibody is pT2609mAb.

5. An antibody which specifically binds to an epitope defined by at least a ten amino acid sequence from human DNA-PKcs, said sequence comprising:
a phosphorylated serine at position S2056, wherein:
said antibody does not bind when S2056 is not phosphorylated.

- 20 6. The antibody of claim 5, wherein:
said antibody is a monoclonal antibody.

- 25 7. The antibody of claim 6, wherein:
said monoclonal antibody is a human monoclonal antibody.

- 30 8. The antibody of claim 5, wherein:
said antibody is pS2056mAb.

9. A method for determining the ability of a test compound to block phosphorylation of human DNA-PKcs, comprising:
providing a sample containing a DNA-PKcs peptide fragment capable of being phosphorylated,
5 combining said test compound with said sample,
inducing phosphorylation of the DNA-PKcs peptide fragment, and
measuring the resulting phosphorylation of said DNA-PKcs peptide fragment at T2609 and/or S2056 in the presence of the test compound.
10. 10. The method of claim 9, wherein:
said measuring step is carried out by measuring the binding of an antibody which specifically binds to an epitope comprising either or both of (a) a phosphorylated serine at position S2056 in human DNA-PKcs or (b) a phosphorylated threonine at position T2609 in human DNA-PKcs.
15
11. The method of either of claims 9 or 10, wherein:
said DNA-PKcs peptide fragment is an isolated peptide having less than 1000 amino acids, and comprising: SEQ ID NO: 4, SEQ ID NO: 5, or sequences having at least 90% homology thereto.
20
12. The method of either of claims 9 or 10, wherein:
said DNA-PKcs peptide fragment is selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13 and SEQ
25 ID NO: 14.
13. The method of either of claims 9 or 10, wherein:
said test compound is selected from the group consisting of: wortmannin, substituted or unsubstituted imidazoles, substituted or unsubstituted pyrazoles, substituted or unsubstituted fluoranthenes, substituted or unsubstituted thiiazoles, substituted or unsubstituted quinolinones, substituted or unsubstituted phthalazinones, and derivatives thereof.
30

14. An isolated peptide having less than 1000 amino acids, comprising:
SEQ ID NO: 4, SEQ ID NO: 5, or sequences having at least 90% homology thereto.
- 5
15. The isolated peptide of claim 14, wherein:
T2609 and/or S2056 are replaced by an amino acid selected from the group consisting of: Valine, Alanine, Glycine, and Leucine.
- 10 16. An isolated polynucleotide encoding the peptide of either claims 14 or 15.
17. The isolated polynucleotide of claim 16, having a sequence selected from the group consisting of: SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26.
- 15
18. A method of measuring radiosensitivity of cells in a subject, comprising:
(a) providing a cell sample from said subject, said sample containing subject's DNA-PKcs,
20 (b) combining said sample with a labelled antibody which binds to phosphorylated residue T2609 or phosphorylated residue S2056 but not the unphosphorylated residues,
(c) removing any unbound antibody from the sample, and
(d) measuring the degree of phosphorylation of the DNA-PKcs by determining the extent of binding of the antibody to the DNA-PKcs,
25 whereby the degree of antibody binding to DNA-PKcs correlates to the degree of phosphorylation, a higher degree of phosphorylation indicating less radiation sensitivity.

30



Fig. 1**Fig. 2**



Fig. 3A**Fig. 3C**


Fig. 3B


Fig. 4A**Fig. 4B**


Fig. 4C






Fig. 5

Fig. 6**A****B**

Time (min): 0 10 30 1h 2h 4h 6h 8h

pS2056pA



SEQUENCE LISTING

<110> Chan, Doug W
Chen, Ping-Chi B
Chen, David J

<120> DNA Dependent Protein Kinase Catalytic Subunit Phosphorylation Sites and Antibodies Thereto

<130> IB-1807 PCT

<140> US 60/375,094

<141> 2003-04-21

<150> US 60/375,094

<151> 2002-04-22

<160> 28

<170> PatentIn version 3.1

<210> 1

<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<221> PEPTIDE
<222> (1)..(14)
<223> HUMAN GENETIC ORIGIN

<220>
<221> MOD_RES
<222> (7)..(7)
<223> PHOSPHORYLATION at T2609

<400> 1

Thr Pro Met Phe Val Glu Thr Gln Ala Ser Gln Gly Thr Cys
1 5 10

<210> 2

<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<221> PEPTIDE
<222> (1)..(14)
<223> HUMAN GENETIC ORIGIN

<220>
<221> MOD_RES
<222> (7)..(7)
<223> PHOSPHORYLATION at S2056

<400> 2

Gln Ser Tyr Ser Tyr Ser Ser Gln Asp Pro Arg Pro Ala Cys
1 5 10

<210> 3

<211> 4128
<212> PRT
<213> Homo sapiens

<400> 3

Met Ala Gly Ser Gly Ala Gly Val Arg Cys Ser Leu Leu Arg Leu Gln
1 5 10 15

Glu Thr Leu Ser Ala Ala Asp Arg Cys Gly Ala Ala Leu Ala Gly His
20 25 30

Gln Leu Ile Arg Gly Leu Gly Gln Glu Cys Val Leu Ser Ser Ser Pro
35 40 45

Ala Val Leu Ala Leu Gln Thr Ser Leu Val Phe Ser Arg Asp Phe Gly
50 55 60

Leu Leu Val Phe Val Arg Lys Ser Leu Asn Ser Ile Glu Phe Arg Glu
65 70 75 80

Cys Arg Glu Glu Ile Leu Lys Phe Leu Cys Ile Phe Leu Glu Lys Met
85 90 95

Gly Gln Lys Ile Ala Pro Tyr Ser Val Glu Ile Lys Asn Thr Cys Thr
100 105 110

Ser Val Tyr Thr Lys Asp Arg Ala Ala Lys Cys Lys Ile Pro Ala Leu
115 120 125

Asp Leu Leu Ile Lys Leu Leu Gln Thr Phe Arg Ser Ser Arg Leu Met
130 135 140

Asp Glu Phe Lys Ile Gly Glu Leu Phe Ser Lys Phe Tyr Gly Glu Leu
145 150 155 160

Ala Leu Lys Lys Ile Pro Asp Thr Val Leu Glu Lys Val Tyr Glu
165 170 175

Leu Leu Gly Leu Leu Gly Glu Val His Pro Ser Glu Met Ile Asn Asn
180 185 190

Ala Glu Asn Leu Phe Arg Ala Phe Leu Gly Glu Leu Lys Thr Gln Met
195 200 205

Thr Ser Ala Val Arg Glu Pro Lys Leu Pro Val Leu Ala Gly Cys Leu
210 215 220

Lys Gly Leu Ser Ser Leu Leu Cys Asn Phe Thr Lys Ser Met Glu Glu
225 230 235 240

Asp Pro Gln Thr Ser Arg Glu Ile Phe Asn Phe Val Leu Lys Ala Ile
245 250 255

Arg Pro Gln Ile Asp Leu Lys Arg Tyr Ala Val Pro Ser Ala Gly Leu
260 265 270

Arg Leu Phe Ala Leu His Ala Ser Gln Phe Ser Thr Cys Leu Leu Asp
275 280 285

Asn Tyr Val Ser Leu Phe Glu Val Leu Leu Lys Trp Cys Ala His Thr
290 295 300

Asn Val Glu Leu Lys Lys Ala Ala Leu Ser Ala Leu Glu Ser Phe Leu
305 310 315 320

Lys Gln Val Ser Asn Met Val Ala Lys Asn Ala Glu Met His Lys Asn
325 330 335

Lys Leu Gln Tyr Phe Met Glu Gln Phe Tyr Gly Ile Ile Arg Asn Val
340 345 350

Asp Ser Asn Asn Lys Glu Leu Ser Ile Ala Ile Arg Gly Tyr Gly Leu
355 360 365

Phe Ala Gly Pro Cys Lys Val Ile Asn Ala Lys Asp Val Asp Phe Met
370 375 380

Tyr Val Glu Leu Ile Gln Arg Cys Lys Gln Met Phe Leu Thr Gln Thr
385 390 395 400

Asp Thr Gly Asp Tyr Arg Val Tyr Gln Met Pro Ser Phe Leu Gln Ser
405 410 415

Val Ala Ser Val Leu Leu Tyr Leu Asp Thr Val Pro Glu Val Tyr Thr
420 425 430

Pro Val Leu Glu His Leu Val Val Met Gln Ile Asp Ser Phe Pro Gln
435 440 445

Tyr Ser Pro Lys Met Gln Leu Val Cys Cys Arg Ala Ile Val Lys Val
450 455 460

Phe Leu Ala Leu Ala Ala Lys Gly Pro Val Leu Arg Asn Cys Ile Ser
465 470 475 480

Thr Val Val His Gln Gly Leu Ile Arg Ile Cys Ser Lys Pro Val Val
485 490 495

Leu Pro Lys Gly Pro Glu Ser Glu Ser Glu Asp His Arg Ala Ser Gly
500 505 510

Glu Val Arg Thr Gly Lys Trp Lys Val Pro Thr Tyr Lys Asp Tyr Val
515 520 525

Asp Leu Phe Arg His Leu Leu Ser Ser Asp Gln Met Met Asp Ser Ile
530 535 540

Leu Ala Asp Glu Ala Phe Phe Ser Val Asn Ser Ser Ser Glu Ser Leu
545 550 555 560

Asn His Leu Leu Tyr Asp Glu Phe Val Lys Ser Val Leu Lys Ile Val
565 570 575

Glu Lys Leu Asp Leu Thr Leu Glu Ile Gln Thr Val Gly Glu Gln Glu
580 585 590

Asn Gly Asp Glu Ala Pro Gly Val Trp Met Ile Pro Thr Ser Asp Pro
595 600 605

Ala Ala Asn Leu His Pro Ala Lys Pro Lys Asp Phe Ser Ala Phe Ile
610 615 620

Asn Leu Val Glu Phe Cys Arg Glu Ile Leu Pro Glu Lys Gln Ala Glu
625 630 635 640

Phe Phe Glu Pro Trp Val Tyr Ser Phe Ser Tyr Glu Leu Ile Leu Gln
645 650 655

Ser Thr Arg Leu Pro Leu Ile Ser Gly Phe Tyr Lys Leu Leu Ser Ile
660 665 670

Thr Val Arg Asn Ala Lys Lys Ile Lys Tyr Phe Glu Gly Val Ser Pro
675 680 685

Lys Ser Leu Lys His Ser Pro Glu Asp Pro Glu Lys Tyr Ser Cys Phe
690 695 700

Ala Leu Phe Val Lys Phe Gly Lys Glu Val Ala Val Lys Met Lys Gln
705 710 715 720

Tyr Lys Asp Glu Leu Leu Ala Ser Cys Leu Thr Phe Leu Leu Ser Leu
725 730 735

Pro His Asn Ile Ile Glu Leu Asp Val Arg Ala Tyr Val Pro Ala Leu
740 745 750

Gln Met Ala Phe Lys Leu Gly Leu Ser Tyr Thr Pro Leu Ala Glu Val
755 760 765

Gly Leu Asn Ala Leu Glu Glu Trp Ser Ile Tyr Ile Asp Arg His Val
770 775 780

Met Gln Pro Tyr Tyr Lys Asp Ile Leu Pro Cys Leu Asp Gly Tyr Leu
785 790 795 800

Lys Thr Ser Ala Leu Ser Asp Glu Thr Lys Asn Asn Trp Glu Val Ser
805 810 815

Ala Leu Ser Arg Ala Ala Gln Lys Gly Phe Asn Lys Val Val Leu Lys
820 825 830

His Leu Lys Lys Thr Lys Asn Leu Ser Ser Asn Glu Ala Ile Ser Leu
835 840 845

Glu Glu Ile Arg Ile Arg Val Val Gln Met Leu Gly Ser Leu Gly Gly
850 855 860

Gln Ile Asn Lys Asn Leu Leu Thr Val Thr Ser Ser Asp Glu Met Met
865 870 875 880

Lys Ser Tyr Val Ala Trp Asp Arg Glu Lys Arg Leu Ser Phe Ala Val
885 890 895

Pro Phe Arg Glu Met Lys Pro Val Ile Phe Leu Asp Val Phe Leu Pro
900 905 910

Arg Val Thr Glu Leu Ala Leu Thr Ala Ser Asp Arg Gln Thr Lys Val

915

920

925

Ala Ala Cys Glu Leu Leu His Ser Met Val Met Phe Met Leu Gly Lys
930 935 940

Ala Thr Gln Met Pro Glu Gly Gly Gln Gly Ala Pro Pro Met Tyr Gln
945 950 955 960

Leu Tyr Lys Arg Thr Phe Pro Val Leu Leu Arg Leu Ala Cys Asp Val
965 970 975

Asp Gln Val Thr Arg Gln Leu Tyr Glu Pro Leu Val Met Gln Leu Ile
980 985 990

His Trp Phe Thr Asn Asn Lys Lys Phe Glu Ser Gln Asp Thr Val Ser
995 1000 1005

Leu Leu Glu Ala Ile Leu Asp Gly Ile Val Asp Pro Val Asp Ser
1010 1015 1020

Thr Leu Arg Asp Phe Cys Gly Arg Cys Ile Arg Glu Phe Leu Lys
1025 1030 1035

Trp Ser Ile Lys Gln Ile Thr Pro Gln Gln Glu Lys Ser Pro
1040 1045 1050

Val Asn Thr Lys Ser Leu Phe Lys Arg Leu Tyr Ser Leu Ala Leu
1055 1060 1065

His Pro Asn Ala Phe Lys Arg Leu Gly Ala Ser Leu Ala Phe Asn
1070 1075 1080

Asn Ile Tyr Arg Glu Phe Arg Glu Glu Glu Ser Leu Val Glu Gln
1085 1090 1095

Phe Val Phe Glu Ala Leu Val Ile Tyr Met Glu Ser Leu Ala Leu
1100 1105 1110

Ala His Ala Asp Glu Lys Ser Leu Gly Thr Ile Gln Gln Cys Cys
1115 1120 1125

Asp Ala Ile Asp His Leu Cys Arg Ile Ile Glu Lys Lys His Val
1130 1135 1140

Ser Leu Asn Lys Ala Lys Lys Arg Arg Leu Pro Arg Gly Phe Pro
1145 1150 1155

Pro Ser Ala Ser Leu Cys Leu Leu Asp Leu Val Lys Trp Leu Leu
1160 1165 1170

Ala His Cys Gly Arg Pro Gln Thr Glu Cys Arg His Lys Ser Ile
1175 1180 1185

Glu Leu Phe Tyr Lys Phe Val Pro Leu Leu Pro Gly Asn Arg Ser
1190 1195 1200

Pro Asn Leu Trp Leu Lys Asp Val Leu Lys Glu Glu Gly Val Ser
1205 1210 1215

Phe Leu Ile Asn Thr Phe Glu Gly Gly Gly Cys Gly Gln Pro Ser
1220 1225 1230

Gly Ile Leu Ala Gln Pro Thr Leu Leu Tyr Leu Arg Gly Pro Phe
1235 1240 1245

Ser Leu Gln Ala Thr Leu Cys Trp Leu Asp Leu Leu Leu Ala Ala
1250 1255 1260

Leu Glu Cys Tyr Asn Thr Phe Ile Gly Glu Arg Thr Val Gly Ala
1265 1270 1275

Leu Gln Val Leu Gly Thr Glu Ala Gln Ser Ser Leu Leu Lys Ala
1280 1285 1290

Val Ala Phe Phe Leu Glu Ser Ile Ala Met His Asp Ile Ile Ala
1295 1300 1305

Ala Glu Lys Cys Phe Gly Thr Gly Ala Ala Gly Asn Arg Thr Ser
1310 1315 1320

Pro Gln Glu Gly Glu Arg Tyr Asn Tyr Ser Lys Cys Thr Val Val
1325 1330 1335

Val Arg Ile Met Glu Phe Thr Thr Thr Leu Leu Asn Thr Ser Pro
1340 1345 1350

Glu Gly Trp Lys Leu Leu Lys Lys Asp Leu Cys Asn Thr His Leu
1355 1360 1365

Met Arg Val Leu Val Gln Thr Leu Cys Glu Pro Ala Ser Ile Gly
1370 1375 1380

Phe Asn Ile Gly Asp Val Gln Val Met Ala His Leu Pro Asp Val
1385 1390 1395

Cys Val Asn Leu Met Lys Ala Leu Lys Met Ser Pro Tyr Lys Asp
1400 1405 1410

Ile Leu Glu Thr His Leu Arg Glu Lys Ile Thr Ala Gln Ser Ile
1415 1420 1425

Glu Glu Leu Cys Ala Val Asn Leu Tyr Gly Pro Asp Ala Gln Val
1430 1435 1440

Asp Arg Ser Arg Leu Ala Ala Val Val Ser Ala Cys Lys Gln Leu
1445 1450 1455

His Arg Ala Gly Leu Leu His Asn Ile Leu Pro Ser Gln Ser Thr
1460 1465 1470

Asp Leu His His Ser Val Gly Thr Glu Leu Leu Ser Leu Val Tyr
1475 1480 1485

Lys Gly Ile Ala Pro Gly Asp Glu Arg Gln Cys Leu Pro Ser Leu
1490 1495 1500

Asp Leu Ser Cys Lys Gln Leu Ala Ser Gly Leu Leu Glu Leu Ala
1505 1510 1515

Phe Ala Phe Gly Gly Leu Cys Glu Arg Leu Val Ser Leu Leu Leu
1520 1525 1530

Asn Pro Ala Val Leu Ser Thr Ala Ser Leu Gly Ser Ser Gln Gly
1535 1540 1545

Ser Val Ile His Phe Ser His Gly Glu Tyr Phe Tyr Ser Leu Phe
1550 1555 1560

Ser Glu Thr Ile Asn Thr Glu Leu Leu Lys Asn Leu Asp Leu Ala
1565 1570 1575

Val Leu Glu Leu Met Gln Ser Ser Val Asp Asn Thr Lys Met Val
1580 1585 1590

Ser Ala Val Leu Asn Gly Met Leu Asp Gln Ser Phe Arg Glu Arg
1595 1600 1605

Ala Asn Gln Lys His Gln Gly Leu Lys Leu Ala Thr Thr Ile Leu
1610 1615 1620

Gln His Trp Lys Lys Cys Asp Ser Trp Trp Ala Lys Asp Ser Pro
1625 1630 1635

Leu Glu Thr Lys Met Ala Val Leu Ala Leu Leu Ala Lys Ile Leu
1640 1645 1650

Gln Ile Asp Ser Ser Val Ser Phe Asn Thr Ser His Gly Ser Phe
1655 1660 1665

Pro Glu Val Phe Thr Thr Tyr Ile Ser Leu Leu Ala Asp Thr Lys
1670 1675 1680

Leu Asp Leu His Leu Lys Gly Gln Ala Val Thr Leu Leu Pro Phe
1685 1690 1695

Phe Thr Ser Leu Thr Gly Gly Ser Leu Glu Glu Leu Arg Arg Val
1700 1705 1710

Leu Glu Gln Leu Ile Val Ala His Phe Pro Met Gln Ser Arg Glu
1715 1720 1725

Phe Pro Pro Gly Thr Pro Arg Phe Asn Asn Tyr Val Asp Cys Met
1730 1735 1740

Lys Lys Phe Leu Asp Ala Leu Glu Leu Ser Gln Ser Pro Met Leu
1745 1750 1755

Leu Glu Leu Met Thr Glu Val Leu Cys Arg Glu Gln Gln His Val
1760 1765 1770

Met Glu Glu Leu Phe Gln Ser Ser Phe Arg Arg Ile Ala Arg Arg
1775 1780 1785

Gly Ser Cys Val Thr Gln Val Gly Leu Leu Glu Ser Val Tyr Glu
1790 1795 1800

Met Phe Arg Lys Asp Asp Pro Arg Leu Ser Phe Thr Arg Gln Ser
1805 1810 1815

Phe Val Asp Arg Ser Leu Leu Thr Leu Leu Trp His Cys Ser Leu
1820 1825 1830

Asp Ala Leu Arg Glu Phe Phe Ser Thr Ile Val Val Asp Ala Ile

1835

1840

1845

Asp Val Leu Lys Ser Arg Phe Thr Lys Leu Asn Glu Ser Thr Phe
1850 1855 1860

Asp Thr Gln Ile Thr Lys Lys Met Gly Tyr Tyr Lys Ile Leu Asp
1865 1870 1875

Val Met Tyr Ser Arg Leu Pro Lys Asp Asp Val His Ala Lys Glu
1880 1885 1890

Ser Lys Ile Asn Gln Val Phe His Gly Ser Cys Ile Thr Glu Gly
1895 1900 1905

Asn Glu Leu Thr Lys Thr Leu Ile Lys Leu Cys Tyr Asp Ala Phe
1910 1915 1920

Thr Glu Asn Met Ala Gly Glu Asn Gln Leu Leu Glu Arg Arg Arg
1925 1930 1935

Leu Tyr His Cys Ala Ala Tyr Asn Cys Ala Ile Ser Val Ile Cys
1940 1945 1950

Cys Val Phe Asn Glu Leu Lys Phe Tyr Gln Gly Phe Leu Phe Ser
1955 1960 1965

Glu Lys Pro Glu Lys Asn Leu Leu Ile Phe Glu Asn Leu Ile Asp
1970 1975 1980

Leu Lys Arg Arg Tyr Asn Phe Pro Val Glu Val Glu Val Pro Met
1985 1990 1995

Glu Arg Lys Lys Lys Tyr Ile Glu Ile Arg Lys Glu Ala Arg Glu
2000 2005 2010

Ala Ala Asn Gly Asp Ser Asp Gly Pro Ser Tyr Met Ser Ser Leu
2015 2020 2025

Ser Tyr Leu Ala Asp Ser Thr Leu Ser Glu Glu Met Ser Gln Phe
2030 2035 2040

Asp Phe Ser Thr Gly Val Gln Ser Tyr Ser Tyr Ser Ser Gln Asp
2045 2050 2055

Pro Arg Pro Ala Thr Gly Arg Phe Arg Arg Arg Glu Gln Arg Asp
2060 2065 2070

Pro Thr Val His Asp Asp Val Leu Glu Leu Glu Met Asp Glu Leu
2075 2080 2085

Asn Arg His Glu Cys Met Ala Pro Leu Thr Ala Leu Val Lys His
2090 2095 2100

Met His Arg Ser Leu Gly Pro Pro Gln Gly Glu Glu Asp Ser Val
2105 2110 2115

Pro Arg Asp Leu Pro Ser Trp Met Lys Phe Leu His Gly Lys Leu
2120 2125 2130

Gly Asn Pro Ile Val Pro Leu Asn Ile Arg Leu Phe Leu Ala Lys
2135 2140 2145

Leu Val Ile Asn Thr Glu Glu Val Phe Arg Pro Tyr Ala Lys His
2150 2155 2160

Trp Leu Ser Pro Leu Leu Gln Leu Ala Ala Ser Glu Asn Asn Gly
2165 2170 2175

Gly Glu Gly Ile His Tyr Met Val Val Glu Ile Val Ala Thr Ile
2180 2185 2190

Leu Ser Trp Thr Gly Leu Ala Thr Pro Thr Gly Val Pro Lys Asp
2195 2200 2205

Glu Val Leu Ala Asn Arg Leu Leu Asn Phe Leu Met Lys His Val
2210 2215 2220

Phe His Pro Lys Arg Ala Val Phe Arg His Asn Leu Glu Ile Ile
2225 2230 2235

Lys Thr Leu Val Glu Cys Trp Lys Asp Cys Leu Ser Ile Pro Tyr
2240 2245 2250

Arg Leu Ile Phe Glu Lys Phe Ser Gly Lys Asp Pro Asn Ser Lys
2255 2260 2265

Asp Asn Ser Val Gly Ile Gln Leu Leu Gly Ile Val Met Ala Asn
2270 2275 2280

Asp Leu Pro Pro Tyr Asp Pro Gln Cys Gly Ile Gln Ser Ser Glu
2285 2290 2295

Tyr Phe Gln Ala Leu Val Asn Asn Met Ser Phe Val Arg Tyr Lys
2300 2305 2310

Glu Val Tyr Ala Ala Ala Glu Val Leu Gly Leu Ile Leu Arg
2315 2320 2325

Tyr Val Met Glu Arg Lys Asn Ile Leu Glu Glu Ser Leu Cys Glu
2330 2335 2340

Leu Val Ala Lys Gln Leu Lys Gln His Gln Asn Thr Met Glu Asp
2345 2350 2355

Lys Phe Ile Val Cys Leu Asn Lys Val Thr Lys Ser Phe Pro Pro
2360 2365 2370

Leu Ala Asp Arg Phe Met Asn Ala Val Phe Phe Leu Leu Pro Lys
2375 2380 2385

Phe His Gly Val Leu Lys Thr Leu Cys Leu Glu Val Val Leu Cys
2390 2395 2400

Arg Val Glu Gly Met Thr Glu Leu Tyr Phe Gln Leu Lys Ser Lys
2405 2410 2415

Asp Phe Val Gln Val Met Arg His Arg Asp Asp Glu Arg Gln Lys
2420 2425 2430

Val Cys Leu Asp Ile Ile Tyr Lys Met Met Pro Lys Leu Lys Pro
2435 2440 2445

Val Glu Leu Arg Glu Leu Leu Asn Pro Val Val Glu Phe Val Ser
2450 2455 2460

His Pro Ser Thr Thr Cys Arg Glu Gln Met Tyr Asn Ile Leu Met
2465 2470 2475

Trp Ile His Asp Asn Tyr Arg Asp Pro Glu Ser Glu Thr Asp Asn
2480 2485 2490

Asp Ser Gln Glu Ile Phe Lys Leu Ala Lys Asp Val Leu Ile Gln
2495 2500 2505

Gly Leu Ile Asp Glu Asn Pro Gly Leu Gln Leu Ile Ile Arg Asn
2510 2515 2520

Phe Trp Ser His Glu Thr Arg Leu Pro Ser Asn Thr Leu Asp Arg
2525 2530 2535

Leu Leu Ala Leu Asn Ser Leu Tyr Ser Pro Lys Ile Glu Val His
2540 2545 2550

Phe Leu Ser Leu Ala Thr Asn Phe Leu Leu Glu Met Thr Ser Met
2555 2560 2565

Ser Pro Asp Tyr Pro Asn Pro Met Phe Glu His Pro Leu Ser Glu
2570 2575 2580

Cys Glu Phe Gln Glu Tyr Thr Ile Asp Ser Asp Trp Arg Phe Arg
2585 2590 2595

Ser Thr Val Leu Thr Pro Met Phe Val Glu Thr Gln Ala Ser Gln
2600 2605 2610

Gly Thr Leu Gln Thr Arg Thr Gln Glu Gly Ser Leu Ser Ala Arg
2615 2620 2625

Trp Pro Val Ala Gly Gln Ile Arg Ala Thr Gln Gln Gln His Asp
2630 2635 2640

Phe Thr Leu Thr Gln Thr Ala Asp Gly Arg Ser Ser Phe Asp Trp
2645 2650 2655

Leu Thr Gly Ser Ser Thr Asp Pro Leu Val Asp His Thr Ser Pro
2660 2665 2670

Ser Ser Asp Ser Leu Leu Phe Ala His Lys Arg Ser Glu Arg Leu
2675 2680 2685

Gln Arg Ala Pro Leu Lys Ser Val Gly Pro Asp Phe Gly Lys Lys
2690 2695 2700

Arg Leu Gly Leu Pro Gly Asp Glu Val Asp Asn Lys Val Lys Gly
2705 2710 2715

Ala Ala Gly Arg Thr Asp Leu Leu Arg Leu Arg Arg Arg Phe Met
2720 2725 2730

Arg Asp Gln Glu Lys Leu Ser Leu Met Tyr Ala Arg Lys Gly Val
2735 2740 2745

Ala Glu Gln Lys Arg Glu Lys Glu Ile Lys Ser Glu Leu Lys Met

2750 2755 2760

Lys Gln Asp Ala Gln Val Val Leu Tyr Arg Ser Tyr Arg His Gly
2765 2770 2775

Asp Leu Pro Asp Ile Gln Ile Lys His Ser Ser Leu Ile Thr Pro
2780 2785 2790

Leu Gln Ala Val Ala Gln Arg Asp Pro Ile Ile Ala Lys Gln Leu
2795 2800 2805

Phe Ser Ser Leu Phe Ser Gly Ile Leu Lys Glu Met Asp Lys Phe
2810 2815 2820

Lys Thr Leu Ser Glu Lys Asn Asn Ile Thr Gln Lys Leu Leu Gln
2825 2830 2835

Asp Phe Asn Arg Phe Leu Asn Thr Thr Phe Ser Phe Phe Pro Pro
2840 2845 2850

Phe Val Ser Cys Ile Gln Asp Ile Ser Cys Gln His Ala Ala Leu
2855 2860 2865

Leu Ser Leu Asp Pro Ala Ala Val Ser Ala Gly Cys Leu Ala Ser
2870 2875 2880

Leu Gln Gln Pro Val Gly Ile Arg Leu Leu Glu Glu Ala Leu Leu
2885 2890 2895

Arg Leu Leu Pro Ala Glu Leu Pro Ala Lys Arg Val Arg Gly Lys
2900 2905 2910

Ala Arg Leu Pro Pro Asp Val Leu Arg Trp Val Glu Leu Ala Lys
2915 2920 2925

Leu Tyr Arg Ser Ile Gly Glu Tyr Asp Val Leu Arg Gly Ile Phe
2930 2935 2940

Thr Ser Glu Ile Gly Thr Lys Gln Ile Thr Gln Ser Ala Leu Leu
2945 2950 2955

Ala Glu Ala Arg Ser Asp Tyr Ser Glu Ala Ala Lys Gln Tyr Asp
2960 2965 2970

Glu Ala Leu Asn Lys Gln Asp Trp Val Asp Gly Glu Pro Thr Glu
2975 2980 2985

Ala Glu Lys Asp Phe Trp Glu Leu Ala Ser Leu Asp Cys Tyr Asn
2990 2995 3000

His Leu Ala Glu Trp Lys Ser Leu Glu Tyr Cys Ser Thr Ala Ser
3005 3010 3015

Ile Asp Ser Glu Asn Pro Pro Asp Leu Asn Lys Ile Trp Ser Glu
3020 3025 3030

Pro Phe Tyr Gln Glu Thr Tyr Leu Pro Tyr Met Ile Arg Ser Lys
3035 3040 3045

Leu Lys Leu Leu Leu Gln Gly Glu Ala Asp Gln Ser Leu Leu Thr
3050 3055 3060

Phe Ile Asp Lys Ala Met His Gly Glu Leu Gln Lys Ala Ile Leu
3065 3070 3075

Glu Leu His Tyr Ser Gln Glu Leu Ser Leu Leu Tyr Leu Leu Gln
3080 3085 3090

Asp Asp Val Asp Arg Ala Lys Tyr Tyr Ile Gln Asn Gly Ile Gln
3095 3100 3105

Ser Phe Met Gln Asn Tyr Ser Ser Ile Asp Val Leu Leu His Gln
3110 3115 3120

Ser Arg Leu Thr Lys Leu Gln Ser Val Gln Ala Leu Thr Glu Ile
3125 3130 3135

Gln Glu Phe Ile Ser Phe Ile Ser Lys Gln Gly Asn Leu Ser Ser
3140 3145 3150

Gln Val Pro Leu Lys Arg Leu Leu Asn Thr Trp Thr Asn Arg Tyr
3155 3160 3165

Pro Asp Ala Lys Met Asp Pro Met Asn Ile Trp Asp Asp Ile Ile
3170 3175 3180

Thr Asn Arg Cys Phe Phe Leu Ser Lys Ile Glu Glu Lys Leu Thr
3185 3190 3195

Pro Leu Pro Glu Asp Asn Ser Met Asn Val Asp Gln Asp Gly Asp
3200 3205 3210

Pro Ser Asp Arg Met Glu Val Gln Glu Gln Glu Glu Asp Ile Ser
3215 3220 3225

Ser Leu Ile Arg Ser Cys Lys Phe Ser Met Lys Met Lys Met Ile
3230 3235 3240

Asp Ser Ala Arg Lys Gln Asn Asn Phe Ser Leu Ala Met Lys Leu
3245 3250 3255

Leu Lys Glu Leu His Lys Glu Ser Lys Thr Arg Asp Asp Trp Leu
3260 3265 3270

Val Ser Trp Val Gln Ser Tyr Cys Arg Leu Ser His Cys Arg Ser
3275 3280 3285

Arg Ser Gln Gly Cys Ser Glu Gln Val Leu Thr Val Leu Lys Thr
3290 3295 3300

Val Ser Leu Leu Asp Glu Asn Asn Val Ser Ser Tyr Leu Ser Lys
3305 3310 3315

Asn Ile Leu Ala Phe Arg Asp Gln Asn Ile Leu Leu Gly Thr Thr
3320 3325 3330

Tyr Arg Ile Ile Ala Asn Ala Leu Ser Ser Glu Pro Ala Cys Leu
3335 3340 3345

Ala Glu Ile Glu Glu Asp Lys Ala Arg Arg Ile Leu Glu Leu Ser
3350 3355 3360

Gly Ser Ser Ser Glu Asp Ser Glu Lys Val Ile Ala Gly Leu Tyr
3365 3370 3375

Gln Arg Ala Phe Gln His Leu Ser Glu Ala Val Gln Ala Ala Glu
3380 3385 3390

Glu Glu Ala Gln Pro Pro Ser Trp Ser Cys Gly Pro Ala Ala Gly
3395 3400 3405

Val Ile Asp Ala Tyr Met Thr Leu Ala Asp Phe Cys Asp Gln Gln
3410 3415 3420

Leu Arg Lys Glu Glu Glu Asn Ala Ser Val Thr Asp Ser Ala Glu
3425 3430 3435

Leu Gln Ala Tyr Pro Ala Leu Val Val Glu Lys Met Leu Lys Ala
3440 3445 3450

Leu Lys Leu Asn Ser Asn Glu Ala Arg Leu Lys Phe Pro Arg Leu
3455 3460 3465

Leu Gln Ile Ile Glu Arg Tyr Pro Glu Glu Thr Leu Ser Leu Met
3470 3475 3480

Thr Lys Glu Ile Ser Ser Val Pro Cys Trp Gln Phe Ile Ser Trp
3485 3490 3495

Ile Ser His Met Val Ala Leu Leu Asp Lys Asp Gln Ala Val Ala
3500 3505 3510

Val Gln His Ser Val Glu Glu Ile Thr Asp Asn Tyr Pro Gln Ala
3515 3520 3525

Ile Val Tyr Pro Phe Ile Ile Ser Ser Glu Ser Tyr Ser Phe Lys
3530 3535 3540

Asp Thr Ser Thr Gly His Lys Asn Lys Glu Phe Val Ala Arg Ile
3545 3550 3555

Lys Ser Lys Leu Asp Gln Gly Gly Val Ile Gln Asp Phe Ile Asn
3560 3565 3570

Ala Leu Asp Gln Leu Ser Asn Pro Glu Leu Leu Phe Lys Asp Trp
3575 3580 3585

Ser Asn Asp Val Arg Ala Glu Leu Ala Lys Thr Pro Val Asn Lys
3590 3595 3600

Lys Asn Ile Glu Lys Met Tyr Glu Arg Met Tyr Ala Ala Leu Gly
3605 3610 3615

Asp Pro Lys Ala Pro Gly Leu Gly Ala Phe Arg Arg Lys Phe Ile
3620 3625 3630

Gln Thr Phe Gly Lys Glu Phe Asp Lys His Phe Gly Lys Gly Gly
3635 3640 3645

Ser Lys Leu Leu Arg Met Lys Leu Ser Asp Phe Asn Asp Ile Thr
3650 3655 3660

Asn Met Leu Leu Leu Lys Met Asn Lys Asp Ser Lys Pro Pro Gly

3665

3670

3675

Asn Leu Lys Glu Cys Ser Pro Trp Met Ser Asp Phe Lys Val Glu
3680 3685 3690

Phe Leu Arg Asn Glu Leu Glu Ile Pro Gly Gln Tyr Asp Gly Arg
3695 3700 3705

Gly Lys Pro Leu Pro Glu Tyr His Val Arg Ile Ala Gly Phe Asp
3710 3715 3720

Glu Arg Val Thr Val Met Ala Ser Leu Arg Arg Pro Lys Arg Ile
3725 3730 3735

Ile Ile Arg Gly His Asp Glu Arg Glu His Pro Phe Leu Val Lys
3740 3745 3750

Gly Gly Glu Asp Leu Arg Gln Asp Gln Arg Val Glu Gln Leu Phe
3755 3760 3765

Gln Val Met Asn Gly Ile Leu Ala Gln Asp Ser Ala Cys Ser Gln
3770 3775 3780

Arg Ala Leu Gln Leu Arg Thr Tyr Ser Val Val Pro Met Thr Ser
3785 3790 3795

Arg Leu Gly Leu Ile Glu Trp Leu Glu Asn Thr Val Thr Leu Lys
3800 3805 3810

Asp Leu Leu Leu Asn Thr Met Ser Gln Glu Glu Lys Ala Ala Tyr
3815 3820 3825

Leu Ser Asp Pro Arg Ala Pro Pro Cys Glu Tyr Lys Asp Trp Leu
3830 3835 3840

Thr Lys Met Ser Gly Lys His Asp Val Gly Ala Tyr Met Leu Met
3845 3850 3855

Tyr Lys Gly Ala Asn Arg Thr Glu Thr Val Thr Ser Phe Arg Lys
3860 3865 3870

Arg Glu Ser Lys Val Pro Ala Asp Leu Leu Lys Arg Ala Phe Val
3875 3880 3885

Arg Met Ser Thr Ser Pro Glu Ala Phe Leu Ala Leu Arg Ser His
3890 3895 3900

Phe Ala Ser Ser His Ala Leu Ile Cys Ile Ser His Trp Ile Leu
3905 3910 3915

Gly Ile Gly Asp Arg His Leu Asn Asn Phe Met Val Ala Met Glu
3920 3925 3930

Thr Gly Gly Val Ile Gly Ile Asp Phe Gly His Ala Phe Gly Ser
3935 3940 3945

Ala Thr Gln Phe Leu Pro Val Pro Glu Leu Met Pro Phe Arg Leu
3950 3955 3960

Thr Arg Gln Phe Ile Asn Leu Met Leu Pro Met Lys Glu Thr Gly
3965 3970 3975

Leu Met Tyr Ser Ile Met Val His Ala Leu Arg Ala Phe Arg Ser
3980 3985 3990

Asp Pro Gly Leu Leu Thr Asn Thr Met Asp Val Phe Val Lys Glu
3995 4000 4005

Pro Ser Phe Asp Trp Lys Asn Phe Glu Gln Lys Met Leu Lys Lys
4010 4015 4020

Gly Gly Ser Trp Ile Gln Glu Ile Asn Val Ala Glu Lys Asn Trp
4025 4030 4035

Tyr Pro Arg Gln Lys Ile Cys Tyr Ala Lys Arg Lys Leu Ala Gly
4040 4045 4050

Ala Asn Pro Ala Val Ile Thr Cys Asp Glu Leu Leu Leu Gly His
4055 4060 4065

Glu Lys Ala Pro Ala Phe Arg Asp Tyr Val Ala Val Ala Arg Gly
4070 4075 4080

Ser Lys Asp His Asn Ile Arg Ala Gln Glu Pro Glu Ser Gly Leu
4085 4090 4095

Ser Glu Glu Thr Gln Val Lys Cys Leu Met Asp Gln Ala Thr Asp
4100 4105 4110

Pro Asn Ile Leu Gly Arg Thr Trp Glu Gly Trp Glu Pro Trp Met
4115 4120 4125

<210> 4

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> PEPTIDE

<222> (1)..(21)

<223> HUMAN GENETIC ORIGIN

<220>

<221> MOD_RES

<222> (11)..(11)

<223> PHOSPHORYLATION at T2609

<400> 4

Ser Thr Val Leu Thr Pro Met Phe Val Glu Thr Gln Ala Ser Gln Gly
1 5 10 15

Thr Leu Gln Thr Arg
20

<210> 5

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> PEPTIDE

<222> (1)..(29)

<223> HUMAN GENETIC ORIGIN

<220>

<221> MOD_RES

<222> (13)..(13)

<223> PHOSPHORYLATION at S2056

<400> 5

Asp Phe Ser Thr Gly Val Gln Ser Tyr Ser Tyr Ser Ser Gln Asp Pro
1 5 10 15

Arg Pro Ala Thr Gly Arg Phe Arg Arg Arg Glu Gln Arg
20 25

<210> 6

<211> 303

<212> PRT

<213> Artificial Sequence

<220>

<221> PEPTIDE

<222> (1)..(303)
<223> HUMAN GENETIC ORIGIN

<220>
<221> MOD_RES
<222> (177)..(177)
<223> PHOSPHORYLATION at S2056

<400> 6

Met Tyr Ser Arg Leu Pro Lys Asp Asp Val His Ala Lys Glu Ser Lys
1 5 10 15

Ile Asn Gln Val Phe His Gly Ser Cys Ile Thr Glu Gly Asn Glu Leu
20 25 30

Thr Lys Thr Leu Ile Lys Leu Cys Tyr Asp Ala Phe Thr Glu Asn Met
35 40 45

Ala Gly Glu Asn Gln Leu Leu Glu Arg Arg Arg Leu Tyr His Cys Ala
50 55 60

Ala Tyr Asn Cys Ala Ile Ser Val Ile Cys Cys Val Phe Asn Glu Leu
65 70 75 80

Lys Phe Tyr Gln Gly Phe Leu Phe Ser Glu Lys Pro Glu Lys Asn Leu
85 90 95

Leu Ile Phe Glu Asn Leu Ile Asp Leu Lys Arg Arg Tyr Asn Phe Pro
100 105 110

Val Glu Val Glu Val Pro Met Glu Arg Lys Lys Tyr Ile Glu Ile
115 120 125

Arg Lys Glu Ala Arg Glu Ala Ala Asn Gly Asp Ser Asp Gly Pro Ser
130 135 140

Tyr Met Ser Ser Leu Ser Tyr Leu Ala Asp Ser Thr Leu Ser Glu Glu
145 150 155 160

Met Ser Gln Phe Asp Phe Ser Thr Gly Val Gln Ser Tyr Ser Tyr Ser
165 170 175

Ser Gln Asp Pro Arg Pro Ala Thr Gly Arg Phe Arg Arg Arg Glu Gln
180 185 190

Arg Asp Pro Thr Val His Asp Asp Val Leu Glu Leu Glu Met Asp Glu
195 200 205

Leu Asn Arg His Glu Cys Met Ala Pro Leu Thr Ala Leu Val Lys His
210 215 220

Met His Arg Ser Leu Gly Pro Pro Gln Gly Glu Glu Asp Ser Val Pro
225 230 235 240

Arg Asp Leu Pro Ser Trp Met Lys Phe Leu His Gly Lys Leu Gly Asn
245 250 255

Pro Ile Val Pro Leu Asn Ile Arg Leu Phe Leu Ala Lys Leu Val Ile
260 265 270

Asn Thr Glu Glu Val Phe Arg Pro Tyr Ala Lys His Trp Leu Ser Pro
275 280 285

Leu Leu Gln Leu Ala Ala Ser Glu Asn Asn Gly Gly Glu Gly Ile
290 295 300

<210> 7

<211> 388

<212> PRT

<213> Artificial Sequence

<220>

<221> PEPTIDE

<222> (1)..(388)

<223> HUMAN GENETIC ORIGIN

<220>

<221> MOD_RES

<222> (177)..(177)

<223> PHOSPHORYLATION at S2056

<400> 7

Met Tyr Ser Arg Leu Pro Lys Asp Asp Val His Ala Lys Glu Ser Lys
1 5 10 15

Ile Asn Gln Val Phe His Gly Ser Cys Ile Thr Glu Gly Asn Glu Leu
20 25 30

Thr Lys Thr Leu Ile Lys Leu Cys Tyr Asp Ala Phe Thr Glu Asn Met
35 40 45

Ala Gly Glu Asn Gln Leu Leu Glu Arg Arg Leu Tyr His Cys Ala
50 55 60

Ala Tyr Asn Cys Ala Ile Ser Val Ile Cys Cys Val Phe Asn Glu Leu
65 70 75 80

Lys Phe Tyr Gln Gly Phe Leu Phe Ser Glu Lys Pro Glu Lys Asn Leu
85 90 95

Leu Ile Phe Glu Asn Leu Ile Asp Leu Lys Arg Arg Tyr Asn Phe Pro
100 105 110

Val Glu Val Glu Val Pro Met Glu Arg Lys Lys Tyr Ile Glu Ile
115 120 125

Arg Lys Glu Ala Arg Glu Ala Ala Asn Gly Asp Ser Asp Gly Pro Ser
130 135 140

Tyr Met Ser Ser Leu Ser Tyr Leu Ala Asp Ser Thr Leu Ser Glu Glu
145 150 155 160

Met Ser Gln Phe Asp Phe Ser Thr Gly Val Gln Ser Tyr Ser Tyr Ser
165 170 175

Ser Gln Asp Pro Arg Pro Ala Thr Gly Arg Phe Arg Arg Arg Glu Gln
180 185 190

Arg Asp Pro Thr Val His Asp Asp Val Leu Glu Leu Glu Met Asp Glu
195 200 205

Leu Asn Arg His Glu Cys Met Ala Pro Leu Thr Ala Leu Val Lys His
210 215 220

Met His Arg Ser Leu Gly Pro Pro Gln Gly Glu Glu Asp Ser Val Pro
225 230 235 240

Arg Asp Leu Pro Ser Trp Met Lys Phe Leu His Gly Lys Leu Gly Asn
245 250 255

Pro Ile Val Pro Leu Asn Ile Arg Leu Phe Leu Ala Lys Leu Val Ile
260 265 270

Asn Thr Glu Glu Val Phe Arg Pro Tyr Ala Lys His Trp Leu Ser Pro
275 280 285

Leu Leu Gln Leu Ala Ala Ser Glu Asn Asn Gly Gly Glu Gly Ile His
290 295 300

Tyr Met Val Val Glu Ile Val Ala Thr Ile Leu Ser Trp Thr Gly Leu
305 310 315 320

Ala Thr Pro Thr Gly Val Pro Lys Asp Glu Val Leu Ala Asn Arg Leu
325 330 335

Leu Asn Phe Leu Met Lys His Val Phe His Pro Lys Arg Ala Val Phe
340 345 350

Arg His Asn Leu Glu Ile Ile Lys Thr Leu Val Glu Cys Trp Lys Asp
355 360 365

Cys Leu Ser Ile Pro Tyr Arg Leu Ile Phe Glu Lys Phe Ser Gly Lys
370 375 380

Asp Pro Asn Ser
385

<210> 8

<211> 821

<212> PRT

<213> Artificial Sequence

<220>

<221> PEPTIDE

<222> (1)..(821)

<223> HUMAN GENETIC ORIGIN

<220>

<221> MOD_RES

<222> (177)..(177)

<223> PHOSPHORYLATION at S2056

<220>

<221> MOD_RES

<222> (730)..(730)

<223> PHOSPHORYLATION at T2609

<400> 8

Met Tyr Ser Arg Leu Pro Lys Asp Asp Val His Ala Lys Glu Ser Lys
1 5 10 15

Ile Asn Gln Val Phe His Gly Ser Cys Ile Thr Glu Gly Asn Glu Leu
20 25 30

Thr Lys Thr Leu Ile Lys Leu Cys Tyr Asp Ala Phe Thr Glu Asn Met
35 40 45

Ala Gly Glu Asn Gln Leu Leu Glu Arg Arg Arg Leu Tyr His Cys Ala
50 55 60

Ala Tyr Asn Cys Ala Ile Ser Val Ile Cys Cys Val Phe Asn Glu Leu

65

70

75

80

Lys Phe Tyr Gln Gly Phe Leu Phe Ser Glu Lys Pro Glu Lys Asn Leu
85 90 95

Leu Ile Phe Glu Asn Leu Ile Asp Leu Lys Arg Arg Tyr Asn Phe Pro
100 105 110

Val Glu Val Glu Val Pro Met Glu Arg Lys Lys Tyr Ile Glu Ile
115 120 125

Arg Lys Glu Ala Arg Glu Ala Ala Asn Gly Asp Ser Asp Gly Pro Ser
130 135 140

Tyr Met Ser Ser Leu Ser Tyr Leu Ala Asp Ser Thr Leu Ser Glu Glu
145 150 155 160

Met Ser Gln Phe Asp Phe Ser Thr Gly Val Gln Ser Tyr Ser Tyr Ser
165 170 175

Ser Gln Asp Pro Arg Pro Ala Thr Gly Arg Phe Arg Arg Arg Glu Gln
180 185 190

Arg Asp Pro Thr Val His Asp Asp Val Leu Glu Leu Glu Met Asp Glu
195 200 205

Leu Asn Arg His Glu Cys Met Ala Pro Leu Thr Ala Leu Val Lys His
210 215 220

Met His Arg Ser Leu Gly Pro Pro Gln Gly Glu Glu Asp Ser Val Pro
225 230 235 240

Arg Asp Leu Pro Ser Trp Met Lys Phe Leu His Gly Lys Leu Gly Asn
245 250 255

Pro Ile Val Pro Leu Asn Ile Arg Leu Phe Leu Ala Lys Leu Val Ile
260 265 270

Asn Thr Glu Glu Val Phe Arg Pro Tyr Ala Lys His Trp Leu Ser Pro
275 280 285

Leu Leu Gln Leu Ala Ala Ser Glu Asn Asn Gly Gly Glu Gly Ile His
290 295 300

Tyr Met Val Val Glu Ile Val Ala Thr Ile Leu Ser Trp Thr Gly Leu
305 310 315 320

Ala Thr Pro Thr Gly Val Pro Lys Asp Glu Val Leu Ala Asn Arg Leu
325 330 335

Leu Asn Phe Leu Met Lys His Val Phe His Pro Lys Arg Ala Val Phe
340 345 350

Arg His Asn Leu Glu Ile Ile Lys Thr Leu Val Glu Cys Trp Lys Asp
355 360 365

Cys Leu Ser Ile Pro Tyr Arg Leu Ile Phe Glu Lys Phe Ser Gly Lys
370 375 380

Asp Pro Asn Ser Lys Asp Asn Ser Val Gly Ile Gln Leu Leu Gly Ile
385 390 395 400

Val Met Ala Asn Asp Leu Pro Pro Tyr Asp Pro Gln Cys Gly Ile Gln
405 410 415

Ser Ser Glu Tyr Phe Gln Ala Leu Val Asn Asn Met Ser Phe Val Arg
420 425 430

Tyr Lys Glu Val Tyr Ala Ala Ala Glu Val Leu Gly Leu Ile Leu
435 440 445

Arg Tyr Val Met Glu Arg Lys Asn Ile Leu Glu Ser Leu Cys Glu
450 455 460

Leu Val Ala Lys Gln Leu Lys Gln His Gln Asn Thr Met Glu Asp Lys
465 470 475 480

Phe Ile Val Cys Leu Asn Lys Val Thr Lys Ser Phe Pro Pro Leu Ala
485 490 495

Asp Arg Phe Met Asn Ala Val Phe Phe Leu Leu Pro Lys Phe His Gly
500 505 510

Val Leu Lys Thr Leu Cys Leu Glu Val Val Leu Cys Arg Val Glu Gly
515 520 525

Met Thr Glu Leu Tyr Phe Gln Leu Lys Ser Lys Asp Phe Val Gln Val
530 535 540

Met Arg His Arg Asp Asp Glu Arg Gln Lys Val Cys Leu Asp Ile Ile
545 550 555 560

Tyr Lys Met Met Pro Lys Leu Lys Pro Val Glu Leu Arg Glu Leu Leu
565 570 575

Asn Pro Val Val Glu Phe Val Ser His Pro Ser Thr Thr Cys Arg Glu
580 585 590

Gln Met Tyr Asn Ile Leu Met Trp Ile His Asp Asn Tyr Arg Asp Pro
595 600 605

Glu Ser Glu Thr Asp Asn Asp Ser Gln Glu Ile Phe Lys Leu Ala Lys
610 615 620

Asp Val Leu Ile Gln Gly Leu Ile Asp Glu Asn Pro Gly Leu Gln Leu
625 630 635 640

Ile Ile Arg Asn Phe Trp Ser His Glu Thr Arg Leu Pro Ser Asn Thr
645 650 655

Leu Asp Arg Leu Leu Ala Leu Asn Ser Leu Tyr Ser Pro Lys Ile Glu
660 665 670

Val His Phe Leu Ser Leu Ala Thr Asn Phe Leu Leu Glu Met Thr Ser
675 680 685

Met Ser Pro Asp Tyr Pro Asn Pro Met Phe Glu His Pro Leu Ser Glu
690 695 700

Cys Glu Phe Gln Glu Tyr Thr Ile Asp Ser Asp Trp Arg Phe Arg Ser
705 710 715 720

Thr Val Leu Thr Pro Met Phe Val Glu Thr Gln Ala Ser Gln Gly Thr
725 730 735

Leu Gln Thr Arg Thr Gln Glu Gly Ser Leu Ser Ala Arg Trp Pro Val
740 745 750

Ala Gly Gln Ile Arg Ala Thr Gln Gln His Asp Phe Thr Leu Thr
755 760 765

Gln Thr Ala Asp Gly Arg Ser Ser Phe Asp Trp Leu Thr Gly Ser Ser
770 775 780

Thr Asp Pro Leu Val Asp His Thr Ser Pro Ser Ser Asp Ser Leu Leu
785 790 795 800

Phe Ala His Lys Arg Ser Glu Arg Leu Gln Arg Ala Pro Leu Lys Ser
805 810 815

Val Gly Pro Asp Phe
820

<210> 9

<211> 440

<212> PRT

<213> Artificial Sequence

<220>

<221> PEPTIDE

<222> (1)..(440)

<223> HUMAN GENETIC ORIGIN

<220>

<221> MOD_RES

<222> (349)..(349)

<223> PHOSPHORYLATION at T2609

<400> 9

Ser Gly Lys Asp Pro Asn Ser Lys Asp Asn Ser Val Gly Ile Gln Leu
1 5 10 15

Leu Gly Ile Val Met Ala Asn Asp Leu Pro Pro Tyr Asp Pro Gln Cys
20 25 30

Gly Ile Gln Ser Ser Glu Tyr Phe Gln Ala Leu Val Asn Asn Met Ser
35 40 45

Phe Val Arg Tyr Lys Glu Val Tyr Ala Ala Ala Ala Glu Val Leu Gly
50 55 60

Leu Ile Leu Arg Tyr Val Met Glu Arg Lys Asn Ile Leu Glu Glu Ser
65 70 75 80

Leu Cys Glu Leu Val Ala Lys Gln Leu Lys Gln His Gln Asn Thr Met
85 90 95

Glu Asp Lys Phe Ile Val Cys Leu Asn Lys Val Thr Lys Ser Phe Pro
100 105 110

Pro Leu Ala Asp Arg Phe Met Asn Ala Val Phe Phe Leu Leu Pro Lys
115 120 125

Phe His Gly Val Leu Lys Thr Leu Cys Leu Glu Val Val Leu Cys Arg
130 135 140

Val Glu Gly Met Thr Glu Leu Tyr Phe Gln Leu Lys Ser Lys Asp Phe
145 150 155 160

Val Gln Val Met Arg His Arg Asp Asp Glu Arg Gln Lys Val Cys Leu
165 170 175

Asp Ile Ile Tyr Lys Met Met Pro Lys Leu Lys Pro Val Glu Leu Arg
180 185 190

Glu Leu Leu Asn Pro Val Val Glu Phe Val Ser His Pro Ser Thr Thr
195 200 205

Cys Arg Glu Gln Met Tyr Asn Ile Leu Met Trp Ile His Asp Asn Tyr
210 215 220

Arg Asp Pro Glu Ser Glu Thr Asp Asn Asp Ser Gln Glu Ile Phe Lys
225 230 235 240

Leu Ala Lys Asp Val Leu Ile Gln Gly Leu Ile Asp Glu Asn Pro Gly
245 250 255

Leu Gln Leu Ile Ile Arg Asn Phe Trp Ser His Glu Thr Arg Leu Pro
260 265 270

Ser Asn Thr Leu Asp Arg Leu Leu Ala Leu Asn Ser Leu Tyr Ser Pro
275 280 285

Lys Ile Glu Val His Phe Leu Ser Leu Ala Thr Asn Phe Leu Leu Glu
290 295 300

Met Thr Ser Met Ser Pro Asp Tyr Pro Asn Pro Met Phe Glu His Pro
305 310 315 320

Leu Ser Glu Cys Glu Phe Gln Glu Tyr Thr Ile Asp Ser Asp Trp Arg
325 330 335

Phe Arg Ser Thr Val Leu Thr Pro Met Phe Val Glu Thr Gln Ala Ser
340 345 350

Gln Gly Thr Leu Gln Thr Arg Thr Gln Glu Gly Ser Leu Ser Ala Arg
355 360 365

Trp Pro Val Ala Gly Gln Ile Arg Ala Thr Gln Gln Gln His Asp Phe
370 375 380

Thr Leu Thr Gln Thr Ala Asp Gly Arg Ser Ser Phe Asp Trp Leu Thr
385 390 395 400

Gly Ser Ser Thr Asp Pro Leu Val Asp His Thr Ser Pro Ser Ser Asp
405 410 415

Ser Leu Leu Phe Ala His Lys Arg Ser Glu Arg Leu Gln Arg Ala Pro
420 425 430

Leu Lys Ser Val Gly Pro Asp Phe
435 440

<210> 10
<211> 200
<212> PRT
<213> Artificial Sequence

<220>
<221> PEPTIDE
<222> (1)..(200)
<223> HUMAN GENETIC ORIGIN

<220>
<221> MOD_RES
<222> (109)..(109)
<223> PHOSPHORYLATION at T2609

<400> 10

Leu Ala Lys Asp Val Leu Ile Gln Gly Leu Ile Asp Glu Asn Pro Gly
1 5 10 15

Leu Gln Leu Ile Ile Arg Asn Phe Trp Ser His Glu Thr Arg Leu Pro
20 25 30

Ser Asn Thr Leu Asp Arg Leu Leu Ala Leu Asn Ser Leu Tyr Ser Pro
35 40 45

Lys Ile Glu Val His Phe Leu Ser Leu Ala Thr Asn Phe Leu Leu Glu
50 55 60

Met Thr Ser Met Ser Pro Asp Tyr Pro Asn Pro Met Phe Glu His Pro
65 70 75 80

Leu Ser Glu Cys Glu Phe Gln Glu Tyr Thr Ile Asp Ser Asp Trp Arg
85 90 95

Phe Arg Ser Thr Val Leu Thr Pro Met Phe Val Glu Thr Gln Ala Ser
100 105 110

Gln Gly Thr Leu Gln Thr Arg Thr Gln Glu Gly Ser Leu Ser Ala Arg
115 120 125

Trp Pro Val Ala Gly Gln Ile Arg Ala Thr Gln Gln Gln His Asp Phe
130 135 140

Thr Leu Thr Gln Thr Ala Asp Gly Arg Ser Ser Phe Asp Trp Leu Thr
145 150 155 160

Gly Ser Ser Thr Asp Pro Leu Val Asp His Thr Ser Pro Ser Ser Asp
165 170 175

Ser Leu Leu Phe Ala His Lys Arg Ser Glu Arg Leu Gln Arg Ala Pro
180 185 190

Leu Lys Ser Val Gly Pro Asp Phe
195 200

<210> 11

<211> 428

<212> PRT

<213> Artificial Sequence

<220>

<221> PEPTIDE

<222> (1)..(428)

<223> HUMAN GENETIC ORIGIN

<220>

<221> MOD_RES

<222> (335)..(335)

<223> PHOSPHORYLATION at T2609

<400> 11

Gln Leu Leu Gly Ile Val Met Ala Asn Asp Leu Pro Pro Tyr Asp Pro
1 5 10 15

Gln Cys Gly Ile Gln Ser Ser Glu Tyr Phe Gln Ala Leu Val Asn Asn
20 25 30

Met Ser Phe Val Arg Tyr Lys Glu Val Tyr Ala Ala Ala Ala Glu Val
35 40 45

Leu Gly Leu Ile Leu Arg Tyr Val Met Glu Arg Lys Asn Ile Leu Glu
50 55 60

Glu Ser Leu Cys Glu Leu Val Ala Lys Gln Leu Lys Gln His Gln Asn
65 70 75 80

Thr Met Glu Asp Lys Phe Ile Val Cys Leu Asn Lys Val Thr Lys Ser
85 90 95

Phe Pro Pro Leu Ala Asp Arg Phe Met Asn Ala Val Phe Phe Leu Leu
100 105 110

Pro Lys Phe His Gly Val Leu Lys Thr Leu Cys Leu Glu Val Val Leu
115 120 125

Cys Arg Val Glu Gly Met Thr Glu Leu Tyr Phe Gln Leu Lys Ser Lys
130 135 140

Asp Phe Val Gln Val Met Arg His Arg Asp Asp Glu Arg Gln Lys Val
145 150 155 160

Cys Leu Asp Ile Ile Tyr Lys Met Met Pro Lys Leu Lys Pro Val Glu
165 170 175

Leu Arg Glu Leu Leu Asn Pro Val Val Glu Phe Val Ser His Pro Ser
180 185 190

Thr Thr Cys Arg Glu Gln Met Tyr Asn Ile Leu Met Trp Ile His Asp
195 200 205

Asn Tyr Arg Asp Pro Glu Ser Glu Thr Asp Asn Asp Ser Gln Glu Ile
210 215 220

Phe Lys Leu Ala Lys Asp Val Leu Ile Gln Gly Leu Ile Asp Glu Asn
225 230 235 240

Pro Gly Leu Gln Leu Ile Ile Arg Asn Phe Trp Ser His Glu Thr Arg
245 250 255

Leu Pro Ser Asn Thr Leu Asp Arg Leu Leu Ala Leu Asn Ser Leu Tyr
260 265 270

Ser Pro Lys Ile Glu Val His Phe Leu Ser Leu Ala Thr Asn Phe Leu
275 280 285

Leu Glu Met Thr Ser Met Ser Pro Asp Tyr Pro Asn Pro Met Phe Glu
290 295 300

His Pro Leu Ser Glu Cys Glu Phe Gln Glu Tyr Thr Ile Asp Ser Asp
305 310 315 320

Trp Arg Phe Arg Ser Thr Val Leu Thr Pro Met Phe Val Glu Thr Gln
 325 330 335

Ala Ser Gln Gly Thr Leu Gln Thr Arg Thr Gln Glu Gly Ser Leu Ser
 340 345 350

Ala Arg Trp Pro Val Ala Gly Gln Ile Arg Ala Thr Gln Gln Gln His
 355 360 365

Asp Phe Thr Leu Thr Gln Thr Ala Asp Gly Arg Ser Ser Phe Asp Trp
 370 375 380

Leu Thr Gly Ser Ser Thr Asp Pro Leu Val Asp His Thr Ser Pro Ser
 385 390 395 400

Ser Asp Ser Leu Leu Phe Ala His Lys Arg Ser Glu Arg Leu Gln Arg
 405 410 415

Ala Pro Leu Lys Ser Val Gly Pro Asp Phe Gly Lys
 420 425

<210> 12

<211> 273

<212> PRT

<213> Artificial Sequence

<220>

<221> PEPTIDE

<222> (1)..(273)

<223> HUMAN GENETIC ORIGIN

<220>

<221> MOD_RES

<222> (180)..(180)

<223> PHOSPHORYLATION at T2609

<400> 12

Glu Arg Gln Lys Val Cys Leu Asp Ile Ile Tyr Lys Met Met Pro Lys
 1 5 10 15

Leu Lys Pro Val Glu Leu Arg Glu Leu Leu Asn Pro Val Val Glu Phe
 20 25 30

Val Ser His Pro Ser Thr Thr Cys Arg Glu Gln Met Tyr Asn Ile Leu
 35 40 45

Met Trp Ile His Asp Asn Tyr Arg Asp Pro Glu Ser Glu Thr Asp Asn
 50 55 60

Asp Ser Gln Glu Ile Phe Lys Leu Ala Lys Asp Val Leu Ile Gln Gly
65 70 75 80

Leu Ile Asp Glu Asn Pro Gly Leu Gln Leu Ile Ile Arg Asn Phe Trp
85 90 95

Ser His Glu Thr Arg Leu Pro Ser Asn Thr Leu Asp Arg Leu Leu Ala
100 105 110

Leu Asn Ser Leu Tyr Ser Pro Lys Ile Glu Val His Phe Leu Ser Leu
115 120 125

Ala Thr Asn Phe Leu Leu Glu Met Thr Ser Met Ser Pro Asp Tyr Pro
130 135 140

Asn Pro Met Phe Glu His Pro Leu Ser Glu Cys Glu Phe Gln Glu Tyr
145 150 155 160

Thr Ile Asp Ser Asp Trp Arg Phe Arg Ser Thr Val Leu Thr Pro Met
165 170 175

Phe Val Glu Thr Gln Ala Ser Gln Gly Thr Leu Gln Thr Arg Thr Gln
180 185 190

Glu Gly Ser Leu Ser Ala Arg Trp Pro Val Ala Gly Gln Ile Arg Ala
195 200 205

Thr Gln Gln Gln His Asp Phe Thr Leu Thr Gln Thr Ala Asp Gly Arg
210 215 220

Ser Ser Phe Asp Trp Leu Thr Gly Ser Ser Thr Asp Pro Leu Val Asp
225 230 235 240

His Thr Ser Pro Ser Ser Asp Ser Leu Leu Phe Ala His Lys Arg Ser
245 250 255

Glu Arg Leu Gln Arg Ala Pro Leu Lys Ser Val Gly Pro Asp Phe Gly
260 265 270

Lys

<210> 13

<211> 140
<212> PRT

<213> Artificial Sequence

<220>

<221> PEPTIDE

<222> (1)..(140)

<223> HUMAN GENETIC ORIGIN

<220>

<221> MOD_RES

<222> (49)..(49)

<223> PHOSPHORYLATION at T2609

<400> 13

Phe Leu Leu Glu Met Thr Ser Met Ser Pro Asp Tyr Pro Asn Pro Met
1 5 10 15

Phe Glu His Pro Leu Ser Glu Cys Glu Phe Gln Glu Tyr Thr Ile Asp
20 25 30

Ser Asp Trp Arg Phe Arg Ser Thr Val Leu Thr Pro Met Phe Val Glu
35 40 45

Thr Gln Ala Ser Gln Gly Thr Leu Gln Thr Arg Thr Gln Glu Gly Ser
50 55 60

Leu Ser Ala Arg Trp Pro Val Ala Gly Gln Ile Arg Ala Thr Gln Gln
65 70 75 80

Gln His Asp Phe Thr Leu Thr Gln Thr Ala Asp Gly Arg Ser Ser Phe
85 90 95

Asp Trp Leu Thr Gly Ser Ser Thr Asp Pro Leu Val Asp His Thr Ser
100 105 110

Pro Ser Ser Asp Ser Leu Leu Phe Ala His Lys Arg Ser Glu Arg Leu
115 120 125

Gln Arg Ala Pro Leu Lys Ser Val Gly Pro Asp Phe
130 135 140

<210> 14

<211> 102

<212> PRT

<213> Artificial Sequence

<220>

<221> PEPTIDE

<222> (1)..(102)

<223> HUMAN GENETIC ORIGIN

<220>
<221> MOD_RES
<222> (9)..(9)
<223> PHOSPHORYLATION at T2609

<400> 14

Val Leu Thr Pro Met Phe Val Glu Thr Gln Ala Ser Gln Gly Thr Leu
1 5 10 15

Gln Thr Arg Thr Gln Glu Gly Ser Leu Ser Ala Arg Trp Pro Val Ala
20 25 30

Gly Gln Ile Arg Ala Thr Gln Gln Gln His Asp Phe Thr Leu Thr Gln
35 40 45

Thr Ala Asp Gly Arg Ser Ser Phe Asp Trp Leu Thr Gly Ser Ser Thr
50 55 60

Asp Pro Leu Val Asp His Thr Ser Pro Ser Ser Asp Ser Leu Leu Phe
65 70 75 80

Ala His Lys Arg Ser Glu Arg Leu Gln Arg Ala Pro Leu Lys Ser Val
85 90 95

Gly Pro Asp Phe Gly Lys
100

<210> 15

<211> 13509
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (6233)..(6235)
<223> Encodes S2056

<220>
<221> misc_feature
<222> (7882)..(7884)
<223> Encodes T2609

<400> 15

ggggcatttc cgggtccggg ccgagcgggc gcacgcgcgg gagcgggact cggcggcatg 60
gcgggctccg gagccggtgt gcgttgctcc ctgctgcggc tgcaggagac cttgtccgct 120
gcggaccgct gcggtgctgc cctggccggt catcaactga tccgcggcct gggcaggaa 180
tgcgtcctga gcagcagccc cgccggtgctg gcattacaga catcttagt ttttccaga 240

gatttcgggtt tgcttgatt tgcggaaag tcactcaaca gtattgaatt tcgtgaatgt 300
agagaagaaa tcctaaagt tttatgtatt ttcttagaaa aaatgggcca gaagatcgca 360
ccttactctg ttgaaaattaa gaacacttgt accagtgtt atacaaaaga tagagctgct 420
aaatgtaaaa ttccagccct ggacccttctt attaagttac ttcatgactt tagaagttct 480
agactcatgg atgaatttaa aattggagaa ttathtagta aattctatgg agaacttgca 540
ttgaaaaaaaaaa aaataccaga tacagttta gaaaaagttat atgagctcct aggattattg 600
ggtaagttc atcctagtga gatgataaat aatgcagaaa acctgttccg cgctttctg 660
ggtaactta agacccagat gacatcagca gtaagagagc ccaaactacc tgttctggca 720
ggatgtctga aggggttgc ctcacttctg tgcaacttca ctaagtccat ggaagaagat 780
ccccagactt caagggagat tttaatttt gtactaaagg caattcgtcc tcagattgt 840
ctgaagagat atgctgtgcc ctcagctggc ttgcgcctat ttgccttgca tgcatctcag 900
tttagcacct gccttctgga caactacgtg tctctatgg aagtcttggaa aaagtgggt 960
gcccacacaa atgtagaatt gaaaaagct gcactttcag ccctggaaatc ctttctgaaa 1020
caggttctta atatggtggc gaaaaatgca gaaatgcata aaaataaact gcagtacttt 1080
atggagcagt ttatggaaat catcagaaat gtggattcga acaacaagga gttatctatt 1140
gctatccgtg gatatggact tttgcagga ccgtgcaagg ttataaacgc aaaagatgtt 1200
gacttcatgt acgttggact cattcagcgc tgcaagcaga tgccctcac ccagacagac 1260
actggtgacg accgtgttta tcagatgcca agttccctcc agtctgttgc aagcgtcttg 1320
ctgtaccttgc acacagttcc tgaggtgtat actccagttc tggagcacct cgtggtgatg 1380
cagatagaca gttcccaca gtacagtcca aaaatgcagc tgggtgttg cagagccata 1440
gtgaagggtt tcctagctt ggcagcaaaa gggccagttc tcaggaattt cattagttact 1500
gtggtgcatc agggtttaat cagaatatgt tctaaaccag tggcccttcc aaagggccct 1560
gagtctgaat ctgaagacca ccgtgctca ggggaagtca gaactggcaa atgaaagggt 1620
ccccacataca aagactacgt ggatctttc agacatctcc tgagctctga ccagatgtat 1680
gattctatggatcagatgtt agcatttttc tctgtgaatt cctccagttga aagtctgaat 1740
catttactttt atgatgaatt tgaaaatcc gttttgaaga ttgttgagaa attggatctt 1800
acacttgaaa tacagactgt tggggaaacaa gagaatggag atgaggcgcc tgggtttgg 1860
atgatcccaa cttcagatcc agcggctaacc ttgcattccag ctaaacctaa agattttcg 1920
gctttcatta acctgggtgga attttgcaga gagattctcc ctgagaaaca agcagaattt 1980
tttgaaccat ggggtgtactc attttcatat gaattaattt tgcaatctac aaggttgccc 2040
ctcatcagtg gtttctacaa attgcttctt attacagtaa gaaatgccaa gaaaataaaaa 2100

tatttcgagg gagttagtcc aaagagtctg aaacactctc ctgaagaccc agaaaagtat	2160
tcttgcttg ctttatttgt gaaatttggc aaagaggtgg cagttaaaat gaagcagtac	2220
aaagatgaac ttttggctc ttgtttgacc tttcttctgt cttgccaca caacatcatt	2280
gaactcgatg ttagagccta cgttcctgca ctgcagatgg ctttcaaact gggcctgagc	2340
tataccccct tggcagaagt aggccctgaat gctctagaag aatggtcaat ttatattgac	2400
agacatgtaa tgcagccta ttacaaagac attctcccct gcctggatgg atacctgaag	2460
acttcagcct tgcagatga gaccaagaat aactgggaag tgcagctct ttctcgggct	2520
gcccagaaag gattnaataa agtggtgtta aagcatctga agaagacaaa gaaccttca	2580
tcaaacgaag caatatcctt agaagaataa agaatttagag tagtacaaat gcttggatct	2640
ctaggaggac aaataaacaa aaatcttctg acagtcacgt cctcagatga gatgatgaag	2700
agctatgtgg cctgggacag agagaagcgg ctgagcttg cagtgcctt tagagagatg	2760
aaacctgtca tttcctgga tgtgttcctg cctcagatca cagaatttagc gtcacagcc	2820
agtgacagac aaactaaagt tgcagcctgt gaactttac atagcatggt tatgttatg	2880
ttgggcaaag ccacgcagat gccagaaggg ggacagggag ccccacccat gtaccagctc	2940
tataagcggc cgttcctgt gctgcttcga cttgcgtgtg atgttgcata ggtgacaagg	3000
caactgtatg agccactagt tatgcagctg attcactggt tcactaacaa caagaaattt	3060
gaaagtcaagg atactgttgc cttaactagaa gctatattgg atgaaattgt ggaccctgtt	3120
gacagtactt taagagattt ttgtggtcgg tgtattcgag aattccttaa atggccatt	3180
aagcaaataa caccacagca gcaggagaag agtccagtaa acaccaaatc gctttcaag	3240
cgactttata gccttgcgct tcaccccaat gcttcaaga ggctgggagc atcacttgcc	3300
tttaataata tctacaggaa attcaggaa gaagagtctc tgggtggaaaca gtttgtgtt	3360
gaaggccttgg tgatatacat ggagagtctg gccttagcac atgcagatga gaagtcctta	3420
ggtacaattc aacagtgtt tgatgccatt gatcacctat gccgcacat tgaaaagaag	3480
catgtttctt taaataaagc aaagaaacga cgtttgcgc gaggatttcc accttccgca	3540
tcattgtgtt tattggatct ggtcaagtgg cttagctc attgtggag gccccagaca	3600
gaatgtcgac acaaatccat tgaactcttt tataaattcg ttccttatt gccaggcaac	3660
agatcccccta atttggcgt gaaagatgtt ctcaaggaag aaggtgtctc ttttctcatc	3720
aacaccccttgg aggggggtgg ctgtggccag ccctcgggca tctggccca gcccaccctc	3780
ttgtaccttc gggggccatt cagcctgcag gccacgctat gctggctgga cctgctcctg	3840
gccgcgttgg agtgctacaa cacgttcatt ggcgagagaa ctgttaggagc gtcacccgtc	3900

ctaggtactg aagcccagtc ttcaacttttgc aaagcagtgg ctttcttctt agaaagcatt	3960
gccatgcacg acattatacgc agcagaaaaag tgctttggca ctggggcagc aggttaacaga	4020
acaagccac aagagggaga aaggtacaac tacagcaa at gcaccgttgc ggtccggatt	4080
atggagtttgc ccacgactct gctaaacacc tccccggaag gatggaagct cctgaagaag	4140
gacttgtgtatc atacacacccat gatgagagtc ctgggtcaga cgctgtgtga gcccgcacgc	4200
atagggtttca acatcgga gatacgatc cgtccagggtt atggctcatc ttccctgatgt ttgtgtgaat	4260
ctgatgaaag ctctaaagat gtccccatac aaagatatcc tagagaccca tctgagagag	4320
aaaataacag cacagagcat tgaggagctt tgtgccgtca acttgttatgg ccctgacgcg	4380
caagtggaca ggagcaggct ggctgctgtt gtgtctgcct gtaaacagct tcacagagct	4440
gggcttctgc ataatatatt accgtctcag tccacagatt tgcatcattc tggtggcaca	4500
gaacttcttt ccctgggttta taaaggcatt gcccctggag atgagagaca gtgtctgcct	4560
tctctagacc tcagttgtaa gcagctggcc agcggacttc tggagttgc ctttgctttt	4620
ggaggactgt gtgagcgcct tttgtgttctt ctccctgaacc cagcgggtgct gtcacacggcg	4680
tccttggca gctcacaggg cagcgtcatc cacttctccc atggggagta tttctatagc	4740
ttgttctcag aaacgatcaa cacggaattt ttgaaaaatc tggatcttgc ttttattggag	4800
ctcatgcagt ctccatgttta taataccaaa atggtgagtg ccgttttgcgaa cggcatgtta	4860
gaccagagct tcagggagcg agcaaaaccag aaacaccaag gactgaaact tgcgactaca	4920
attctgcaac actggaagaa gtgtgattca tgggtggccca aagattcccc tctcgaaact	4980
aaaatggcag tgctggcctt actggcaaaa attttacaga ttgattcatc tttatctttt	5040
aatacaagtc atggttcatt ccctgaagtc tttacaacat atattatgtt acttgctgac	5100
acaaagctgg atctacat tttttttttt aaaggccaa gctgtcaactc ttcttccatt ctccaccagc	5160
ctcactggag gcagtctggta ggaacttaga cgtgttctgg agcagctcat cgttgctcac	5220
ttccccatgc agtccagggta atttccatca ggaactccgc ggttcaataa ttatgtggac	5280
tgcattgaaaa agtttctaga tgcattggaa ttatctcaaa gccctatgtt gttggatttg	5340
atgacagaag ttctttgtcg ggaacacgcg catgtcatgg aagaattatt tcaatccagt	5400
ttcaggagga ttgccagaag gggttcatgt gtcacacaag taggccttct ggaaagcgtg	5460
tatgaaatgt tcaggaagga tgaccccccgc ctaagttca cacgccagtc ctttgcggac	5520
cgctccctcc tcactctgct gtggcactgt agcctggatg ctttgcggatc attcttcagc	5580
acaattgtgg tggatgccat tgatgtgttgc aagtccaggt ttacaaagct aaatgaatct	5640
acctttgata ctcaaatac caagaagatg ggctactata agattctaga cgtgatgtat	5700
tctcgccatc ccaaagatga tggatcatgc aaggaatcaa aaattaatca agtttccat	5760

ggctcggtta ttacagaagg aaatgaactt acaaagacat tgattaaatt gtgctacgat 5820
gcattttacag agaacatggc aggagagaat cagctgctgg agaggagaag actttaccat 5880
tgtgcagcat acaactgcgc catatctgtc atctgctgtg tcttcataatga gttaaaattt 5940
taccaagggtt ttctgttttag tgaaaaacca gaaaagaact tgcttatttt tgaaaatctg 6000
atcgacctga agcgccgcta taatttccct gtagaagttg aggttcctat ggaaagaaag 6060
aaaaagtaca ttgaaattag gaaagaagcc agagaagcag caaatggggg ttcagatgg 6120
ccttcctata tgtcttcct gtcataatttgc gcagacagta ccctgagtga ggaaatgagt 6180
caatttgatt tctcaaccgg agttcagagc tattcataca gctcccaaga ccctagacct 6240
gccactggtc gttttcgag acgggagcag cgggacccc cggtgcattga tgatgtgctg 6300
gagctggaga tggacgagct caatcggcat gagtgcattgg cgccccctgac ggccctggtc 6360
aagcacatgc acagaagcct gggcccgcc caaggagaag aggattcagt gccaaagagat 6420
cttccttctt ggatgaaatt cctccatggc aaactggaa atccaatagt accattaaat 6480
atccgtctct tcttagccaa gcttgttatt aatacagaag aggtcttcg cccttacgcg 6540
aagcactggc ttagccctt gctgcagctg gctgcttctg aaaacaatgg aggagaagga 6600
attcactaca tggtggttga gatagtggcc actattctt catggacagg cttggccact 6660
ccaacagggg tccctaaaga tgaagtgttgc gcaaatcgat tgcttaattt cctaatgaaa 6720
catgtcttc atccaaaaag agctgtgtt agacacaacc ttgaaattat aaagaccctt 6780
gtcgagtgct ggaaggattt gttatccatc ctttataggt taatatttga aaagtttcc 6840
ggtaaagatc ctaattctaa agacaactca gtagggattc aattgctagg catcgatgatg 6900
gccaatgacc tgcctcccta tgacccacag tgtggcatcc agagtagcga atacttccag 6960
gctttggtga ataatatgtc ctttgtaaga tataaagaag tgtatgccgc tgcagcagaa 7020
gttctaggac ttatacttcg atatgtttagt gagagaaaaa acatactggc ggagtctctg 7080
tgtgaactgg ttgcgaaaca attgaagcaa catcagaata ctatggagga caagtttatt 7140
gtgtgcttgc acaaagtgc caagagctc cttccatc cttgttgc cagacagggtt catgaatgct 7200
gtgttcttc tgctgccaaa atttcatggc gtgttggaaa cactctgtct ggaggtggta 7260
ctttgtcgtg tggagggaaat gacagagctg tacttccagt taaagagcaa ggacttcgtt 7320
caagtcatga gacatagaga tggatgaaaga caaaaagtat gtttggacat aatttataag 7380
atgatgccaa agttaaaacc agtagaactc cgagaacttc tgaaccccggt tgtggatttc 7440
gtttcccatc cttctacaac atgttagggaa caaatgtata atattctcat gtggattcat 7500
gataattaca gagatccaga aagtgagaca gataatgact cccagggaaat atttaagttg 7560

gcaaaagatg tgctgattca aggattgatc gatgagaacc ctggacttca attaattatt	7620
cggaaatttct ggagccatga aactaggta cttcaaata cttggaccg gttgtggca	7680
ctaaattcct tatattctcc taagatagaa gtgcacttt taagtttagc aacaaatttt	7740
ctgctcgaaa tgaccagcat gagcccagat tatccaaacc ccatgttcga gcattcttg	7800
tcagaatgct aatttcagga atataccatt gattctgatt ggcgttccg aagtactgtt	7860
ctcactccga tgggttggga gacccaggcc tcccaaggca ctctccagac ccgtacccag	7920
gaagggtccc tctcagctcg ctggccagtg gcagggcaga taaggccac ccagcagcag	7980
catgacttca cactgacaca gactgcagat ggaagaagct catttgcattt gctgaccggg	8040
agcagcactg acccgcttgt cgaccacacc agtccctcat ctgactcctt gctgtttgcc	8100
cacaagagga gtgaaaggaa acagagagca cccttgaagt cagtggggcc tgattttggg	8160
aaaaaaaggc tgggccttcc aggggacgag gtggataaca aagtgaaagg tgccggccggc	8220
cggacggacc tactacgact ggcgcagacgg ttatgaggg accaggagaa gctcagtttgc	8280
atgtatgcca gaaaaggcgt tgctgagcaa aaacgagaga aggaaatcaa gagtgagttt	8340
aaaatgaagc aggtatcccc ggtcggtctg tacagaagct accggcacgg agaccccttgc	8400
gacattcaga tcaagcacag cagcctcatc accccgttac agggcgtggc ccagaggac	8460
ccaataattt caaaacagct cttagcagc ttgtttctg gaattttgaa agagatggat	8520
aaatttttaaga cactgtctga aaaaaacaac atcactcaaa agttgcttca agacttcaat	8580
cgttttctta ataccacatt ctctttctt ccacccttttgc tctcttgat tcaggacatt	8640
agctgtcagc acgcagccct gctgagccct gaccgcgg ctgttagcgc tgggtgcctg	8700
gccagcctac agcagccctgt ggcgcattccgc ctgcttagagg aggctctgct ccgcctgctg	8760
cctgctgagc tgcctgccaa gcgagtcgtt gggaaaggccc gcctccctcc tgatgtcctc	8820
agatgggtgg agcttgctaa gctgtataga tcaattggag aatacgacgt cctccgtggg	8880
atttttacca gtgagatagg aacaaagcaa atcactcaga gtgcattatt agcagaagcc	8940
agaagtgatt attctgaagc tgctaaggcag tatgtatgagg ctctcaataa acaagactgg	9000
gttagatggtg agcccacaga agccgagaag gatTTTGGG aacttgcattt ctttgcatttgc	9060
tacaaccacc ttgctgagtg gaaatcactt gaatactgtt ctacagccag tatagacagt	9120
gagaacccccc cagacctaaa taaaatctgg agtgaaccat ttatcagga aacatatcta	9180
ccttacatga tccgcagcaa gctgaagctg ctgctccagg gagaggctga ccagtcctg	9240
ctgacattta ttgacaaagc tatgcacggg gagtccaga aggcttgcatttgc	9300
tacagtcaag agctgagtct gctttacctc ctgcaagatg atgttgcacag agccaaatata	9360
tacattcaaa atggcattca gagttttatg cagaattatt ctgttgcatttgc	9420

caccaaagta gactcaccaa attgcagtct gtacaggctt taacagaaaat tcaggagttc 9480
atcagcttta taagcaaaca aggcaattta tcatctcaag ttccccttaa gagacttctg 9540
aacacctgga caaacagata tccagatgtc aaaatggacc caatgaacat ctgggatgac 9600
atcatcacaa atcgatgtt ctttcagc aaaatagagg agaagcttac ccctcttcca 9660
gaagataata gtatgaatgt ggatcaagat ggagaccccga gtgacaggat ggaagtgcaa 9720
gagcaggaag aagatatcag ctccctgatc aggagttgca agtttccat gaaaatgaag 9780
atgatagaca gtgccccgaa gcagaacaat ttctcacttg ctatgaaact actgaaggag 9840
ctgcataaaag agtcaaaaac cagagacgt tggctggta gctgggtgca gagctactgc 9900
cgcctgagcc actgcccggag ccgggtcccag ggctgctctg agcaggtgct cactgtgctg 9960
aaaacagtct ctttgttggaa tgagaacaac gtgtcaagct acttaagcaa aaatattctg 10020
gctttccgtg accagaacat tctcttgggt acaacttaca ggatcatagc gaatgctctc 10080
agcagtgagc cagcctgcct tgctgaaatc gaggaggaca aggctagaag aatcttagag 10140
ctttctggat ccagttcaga ggattcagag aaggtgatcg cgggtctgta ccagagagca 10200
ttccagcacc tctctgaggc tgtgcaggcg gctgaggagg aggcccagcc tccctcctgg 10260
agctgtggc ctgcagctgg ggtgattgat gcttacatga cgctggcaga tttctgtgac 10320
caacagctgc gcaaggagga agagaatgca tcagttattt attctgcaga actgcaggcg 10380
tatccagcac ttgtggtgga gaaaatgttggaa aagctttaa aattaaatttcaatgaagcc 10440
agattgaagt ttcccttagatt acttcagatt atagaacggt atccagagga gactttgagc 10500
ctcatgacaa aagagatctc ttccgttccc tgctggcagt tcatacgtc gatcagccac 10560
atggtggcct tactggacaa agaccaagcc gttgctgttc agcactctgt ggaagaaatc 10620
actgataact acccgcaggc tattgtttat cccttcataca taagcagcga aagctattcc 10680
ttcaaggata cttctactgg tcataagaat aaggagtttggcaaggat taaaagtaag 10740
ttggatcaag gaggagtgtat ctaagatttt attaatgcct tagatcagct ctctaattcct 10800
gaactgctct ttaaggattt gacaaatgtat gtaagagctg aactagcaaa aacccctgta 10860
aataaaaaaaa acattgaaaaa aatgtatgaa agaatgtatg cagccttggg tgacccaaag 10920
gctccaggcc tggggccctt tagaaggaag tttattcaga cttttggaaa agaattttgat 10980
aaacatttttggaaaggagg ttctaaacta ctgagaatga agctcagtgat cttcaacgac 11040
attaccaaca tgctactttt aaaaatgaac aaagactcaa agccccctgg gaatctgaaa 11100
gaatgttcac cctggatgag cgacttcaaa gtggagttcc tgagaaatga gctggagatt 11160
cccggtcagt atgacggtag gggaaagcca ttgccagagt accacgtgcg aatcgccggg 11220

tttgatgagc gggtgacagt catggcgtct ctgcgaaggc ccaagcgcat catcatccgt 11280
ggccatgacg agagggaaaca cccttcctg gtgaagggtg gcgaggacct gcggcaggac 11340
cagcgcgtgg agcagcttt ccaggtcatg aatgggatcc tggcccaaga ctccgcctgc 11400
agccagaggg ccctgcagct gaggacctat agcgttgtgc ccatgaccc tc caggttagga 11460
ttaattgagt ggcttgaaaa tactgttacc ttgaaggacc ttctttgaa caccatgtcc 11520
caagaggaga aggccggctta cctgagtgat cccagggcac cgccgtgtga atataaagat 11580
tggctgacaa aaatgtcagg aaaacatgat gttggagctt acatgcta at gtataaggc 11640
gctaatcgta ctgaaacagt cacgtctttt agaaaacgag aaagtaaagt gcctgctgat 11700
ctcttaaagc gggccttcgt gaggatgagt acaagccctg aggcttcctt ggcgctccgc 11760
tcccacttcg ccagctctca cgctctgata tgcatcagcc actggatcct cgggatttgg 11820
gacagacatc tgaacaactt tatggtggcc atggagactg gcggcgtgtat cgggatcgac 11880
tttgggcatg cgtttggatc cgctacacag tttctgccag tccctgagtt gatgcctttt 11940
cggtctaactc gccagtttat caatctgatg ttaccaatga aagaaacggg ccttatgtac 12000
agcatcatgg tacacgcact ccgggccttc cgctcagacc ctggcctgct caccaacacc 12060
atggatgtgt ttgtcaagga gccctcctttt gattggaaaa attttgaaca gaaaatgctg 12120
aaaaaaggag ggtcatggat tcaagaaata aatgttgctg aaaaaaattt gtaaaaaa 12180
cagaaaaat gttacgctaa gagaaaatgtt gcagggccatccatcactgtt cattacttgt 12240
gatgagctac tcctgggtca tgagaaggcc cctgccttca gagactatgt ggctgtggca 12300
cgaggaagca aagatcacaa cattcgtgcc caagaaccag agagtggct ttcagaagag 12360
actcaagtga agtgcctgat ggaccaggca acagacccca acatccttgg cagaacctgg 12420
gaaggatggg agccctggat gtgaggtctg tggaggtctg cagatagaaaa gcattacatt 12480
gtttaaagaa tctactatac tttgggtggc agcattccat gagctgattt tcctgaaaca 12540
ctaaagagaa atgtctttt tgctacagtt tcgtacatg agtttaaatc aagattatga 12600
tgagtaaatg tgtatgggtt aaatcaaaga taaggttata gtaacatcaa agattaggt 12660
aggtttatag aaagatagat atccaggctt accaaagtat taagtcaaga atataatatg 12720
tgatcagctt tcaaaggcatt tacaagtgc gcaagttgt gaaacagctg tctccgtaaa 12780
tggaggaaat gtggggaaagc ctggaaatgc cttctgggtt ctggcacatt ggaaagcaca 12840
ctcagaaggc ttcatcacca agatttggg agagtaaagc taagtatagt tgatgtaca 12900
ttgtagaagc agcataggaa caataagaac aataggtaaa gctataatta tggcttat 12960
tttagaaatga ctgcatttga tatttttagga tattttcttca gttttttcc tttcattttt 13020
ttctcttcttca gttttgacat tttatgatag atttgctctc tagaaggaaa cgtctttatt 13080

taggagggca aaaattttgg tcatagcatt cactttgct attccaatct acaactggaa 13140
gatacataaa agtgctttgc attgaatttg ggataacttc aaaaatccca tgggttgtt 13200
tagggatagt actaaggcatt tcagttccag gagaataaaaa gaaattccta tttgaaatga 13260
attcctcatt tggagggaaaa aaagcatgca ttctagcaca acaagatgaa attatggaat 13320
acaaaagtgg ctccctccca tgtgcagtcc ctgtcccccc ccgccagtc tccacaccca 13380
aactgtttct gattggcttt tagcttttg ttgtttttt tttccttct aacacttgta 13440
tttggaggct cttctgtgat tttgagaagt atactcttga gtgttaata aagtttttt 13500
ccaaaagta 13509

<210> 16

<211> 63

<212> DNA

<213> Artificial Sequence

<220>

<223> cDNA sequence encoding the 2599-2619 peptide

<220>

<221> CDS

<222> (1)..(63)

<223> HUMAN GENETIC ORIGIN

<220>

<221> misc_feature

<222> (31)..(33)

<223> encodes T2609 residue

<400> 16

agtactgttc tcactccgat gtttgtggag acccaggcct cccagggcac tctccagacc 60

cgt 63

<210> 17

<211> 87

<212> DNA

<213> Artificial sequence

<220>

<223> cDNA sequence encoding the 2044-2072 peptide

<220>

<221> CDS

<222> (1)..(87)

<223> HUMAN GENETIC ORIGIN

<220>

<221> misc_feature

<222> (37)..(37)

<223> encodes S2056 residue

<400> 17

gatttctcaa ccggagttca gagctattca tacagctccc aagaccctag acctgccact 60
ggtcgtttc ggagacggga gcagcgg 87

<210> 18

<211> 909

<212> DNA

<213> Artificial Sequence

<220>

<223> cDNA sequence encoding the 1879-2182 peptide

<220>

<221> CDS

<222> (1)..(909)

<223> HUMAN GENETIC ORIGIN

<220>

<221> misc_feature

<222> (529)..(529)

<223> encodes S2056 residue

<400> 18

atgtattctc gccttccaa agatgatgtt catgctaagg aatcaaaaat taatcaagtt 60
ttccatggct cgtgttattac agaaggaaat gaacttacaa agacattgtat taaattgtgc 120
tacgatgcat ttacagagaa catggcagga gagaatcagc tgctggagag gagaagactt 180
taccattgtg cagcatacaa ctgcgcata tctgtcatct gctgtgtctt caatgagtt 240
aaattttacc aaggtttct gtttagtgaa aaaccagaaa agaacttgct tattttgaa 300
aatctgatcg acctgaagcg ccgctataat tttcctgttag aagttgaggt tcctatggaa 360
agaaaagaaaa agtacattga aatttaggaaa gaagccagag aagcagcaaa tggggattca 420
gatggtcctt cctatatgtc ttccctgtca tatttggcag acagtaccct gagtgaggaa 480
atgagtcaat ttgatttctc aaccggagtt cagagctatt catacagctc ccaagaccct 540
agacctgcca ctggtcgttt tcggagacgg gagcagcggg accccacgggt gcatgtatgat 600
gtgctggagc tggagatgga cgagctcaat cggcatgagt gcatggcgcc cctgacggcc 660
ctggtcaagc acatgcacag aagcctgggc ccgcctcaag gagaagagga ttcagtgcca 720
agagatcttc cttcttggat gaaattcctc catggcaaac tggaaatcc aatagtagcca 780
ttaaatatcc gtctcttctt agccaagctt gttattaata cagaagaggt ctttcgcctt 840
tacgcgaagc actggcttag ccccttgctg cagctggctg cttctgaaaa caatggagga 900
gaaggaatt 909

<210> 19

<211> 1164

<212> DNA

<213> Artificial sequence

<220>

<223> Cloned DNA sequence encoding the 1879-2267 peptide

<220>

<221> CDS

<222> (1)..(1164)

<223> HUMAN GENETIC ORIGIN

<220>

<221> misc_feature

<222> (529)..(531)

<223> encodes S2056 residue

<400> 19

atgtattctc gccttccaa agatgatgtt catgctaagg aatcaaaaat taatcaagtt	60
ttccatggct cgtgttattac agaaggaaat gaacttacaa agacattgat taaattgtgc	120
tacgatgcat ttacagagaa catggcagga gagaatcagc tgctggagag gagaagactt	180
taccattgtg cagcatacaa ctgcgccata tctgtcatct gctgtgtctt caatgagttt	240
aaattttacc aaggtttct gtttagtgaa aaaccagaaa agaacttgct tattttgaa	300
aatctgatcg acctgaagcg ccgctataat tttcctgttag aagttgaggt tcctatggaa	360
agaaaagaaaa agtacattga aatttagaaaa gaagccagag aagcagcaaa tggggattca	420
gatggtcctt cctatatgtc ttcccgtca tatttggcag acagtaccct gagtgaggaa	480
atgagtcaat ttgatttctc aaccggagtt cagagctatt catacagctc ccaagaccct	540
agacctgcca ctggtcgttt tcggagacgg gagcagcggg accccacggc gcatgatgat	600
gtgctggagc tggagatgga cgagctaat cggcatgagt gcatggcgcc cctgacggcc	660
ctggtaagc acatgcacag aagcctgggc ccgcctcaag gagaagagga ttcagtgcca	720
agagatcttc cttcttggat gaaattcctc catggcaaac tggaaatcc aatagtagcca	780
ttaaatatcc gtctcttctt agccaagctt gttattaata cagaagaggt ctttcgcctt	840
tacgcgaagc actggcttag ccccttgctg cagctggctg cttctgaaaa caatggagga	900
gaaggaattc actacatggt ggttgagata gtggccacta ttctttcatg gacaggcttg	960
gccactccaa caggggtccc taaagatgaa gtgttagcaa atcgattgct taatttccta	1020
atgaaacatg tctttcatcc aaaaagagct gtgttagac acaaccttga aattataaag	1080
acccttgcg agtgctggaa ggattgttta tccatccctt ataggtaat attgaaaag	1140

ttttccggta aagatcctaa ttct

1164

<210> 20

<211> 2463

<212> DNA

<213> Artificial Sequence

<220>

<223> cDNA sequence encoding the 1879-2700 peptide

<220>

<221> CDS

<222> (1)..(2463)

<223> HUMAN GENETIC ORIGIN

<220>

<221> misc_feature

<222> (529)..(531)

<223> encodes S2056 residue

<220>

<221> misc_feature

<222> (2188)..(2190)

<223> encodes T2609 residue

<400> 20

atgtattctc gccttccaa agatgatgtt catgctaagg aatcaaaaat taatcaagtt	60
ttccatggct cgtgttattac agaaggaaat gaacttacaa agacatttgat taaaattgtgc	120
tacgatgcat ttacagagaa catggcagga gagaatcagc tgctggagag gagaagactt	180
taccattgtg cagcatacaa ctgcgccata tctgtcatct gctgtgtctt caatgagttt	240
aaattttacc aaggttttct gtttagtgaa aaaccagaaa agaacttgct tattttgaa	300
aatctgatcg acctgaagcg ccgcataat tttcctgttag aagttgaggt tcctatggaa	360
agaaaagaaaa agtacattga aatttaggaaa gaagccagag aagcagcaaa tggggattca	420
gatggtcctt cctatatgtc ttcccgtca tattttggcag acagtaccct gagtgaggaa	480
atgagtcaat ttgatttctc aaccggagtt cagagctatt catacagctc ccaagaccct	540
agacctgcca ctggcgttt tcggagacgg gagcagcggg accccacgggt gcatgatgat	600
gtgctggagc tggagatgga cgagctaat cggcatgagt gcatggcgcc cctgacggcc	660
ctggtaagc acatgcacag aagcctgggc ccgcctcaag gagaagagga ttcagtgcca	720
agagatcttc cttcttggat gaaattcctc catggcaaac tggaaatcc aatagtagcca	780
ttaaatatcc gtctcttctt agccaagctt gttattaata cagaagaggt ctttcgcctt	840
tacgcgaagc actggcttag ccccttgctg cagctggctg cttctgaaaa caatggagga	900
gaaggaattc actacatggt gggttagata gtggccacta ttcttcatg gacaggcttgc	960

gccactccaa caggggtccc taaagatgaa gtgttagcaa atcgattgct taatttccta	1020
atgaaaacatg tccttcatcc aaaaagagct gtgttagac acaaccttga aattataaaag	1080
acccttgcg agtgctggaa ggattgtttc tccatccctt ataggtaat atttggaaag	1140
ttttccggta aagatcctaa ttctaaagac aactcagtag ggattcaatt gctaggcatc	1200
gtgatggcca atgacctgcc tccctatgac ccacagtgtg gcatccagag tagcgaatac	1260
ttccaggcctt tggtgaataa tatgtccttt gtaagatata aagaagtgt a tgccgctgca	1320
gcagaagttc taggacttat acttcgatat gttatggaga gaaaaaacat actggaggag	1380
tctctgtgtg aactgggtgc gaaacaattt aagcaacatc agaatactat ggaggacaag	1440
tttattgtgt gcttgaacaa agtgaccaag agcttccctc ctcttcgaga caggttcatg	1500
aatgctgtgt tctttctgct gccaaaattt catggagtgt tgaaaacact ctgtctggag	1560
gtggtaacttt gtcgtgtgga gggaatgaca gagctgtact tccagttaaa gagcaaggac	1620
ttcggtcaag tcatgagaca tagagatgat gaaagacaaa aagtatgtt ggacataatt	1680
tataagatga tgccaaagtt aaaaccagta gaactccgag aacttctgaa ccccggttg	1740
gaattcgttt cccatccttc tacaacatgt agggacaaa tgtataatat tctcatgtgg	1800
attcatgata attacagaga tccagaaagt gagacagata atgactcccc gggaaatattt	1860
aagttggcaa aagatgtgct gattcaagga ttgatcgatg agaaccctgg acttcaatta	1920
attattcgaa atttctggag ccatgaaact aggttacctt caaataccctt ggaccgggttg	1980
ctggcactaa attccttata ttctcctaag atagaagtgc acttttaag tttagcaaca	2040
aattttctgc tcgaaatgac cagcatgagc ccagattatc caaaccctt gttcgagcat	2100
cctctgtcag aatgcgaatt tcaggaatat accattgatt ctgattggcg tttccgaagt	2160
actgttctca ctccgatgtt tgtggagacc caggcctccc agggcactct ccagaccgt	2220
acccaggaag ggtccctctc agctcgctgg ccagtggcaag ggcagataag ggccacccag	2280
cagcagcatg acttcacact gacacagact gcagatggaa gaagctcatt tgattggctg	2340
accgggagca gcactgaccc gctggtcgac cacaccagtc cctcatctga ctccttgctg	2400
tttgcccaca agaggagtga aagggtacag agagcacccct tgaagtcagt gggcctgat	2460
ttt	2463

<210> 21

<211> 1320

<212> DNA

<213> Artificial sequence

<220>

<223> cDNA sequence encoding the 2261-2700 peptide

<220>
<221> CDS
<222> (1)..(1320)
<223> HUMAN GENETIC ORIGIN

<220>
<221> misc_feature
<222> (1045)..(1047)
<223> encodes T2609 residue

<400> 21

tccggtaaag atcctaattc taaagacaac tcagtaggga ttcaattgct aggcatcg	60
atggccaatg acctgcctcc ctatgaccgc cagtgtggca tccagagtag cgaataactc	120
caggcttgg tgaataatat gtccttgta agatataaag aagtgtatgc cgctgcagca	180
gaagttctag gacttatact tcgatatgtt atggagagaa aaaacatact ggaggagtct	240
ctgtgtgaac tggttgcgaa acaattgaag caacatcaga atactatgga ggacaagttt	300
atttgtgtgct tgaacaaaagt gaccaagagc ttccctcctc ttgcagacag gttcatgaat	360
gctgtgttct ttctgctgcc aaaatttcat ggagtgttga aaacactctg tctggaggtg	420
gtactttgtc gtgtggaggg aatgacagag ctgtacttcc agttaaagag caaggacttc	480
gttcaagtca tgagacatag agatgatgaa agacaaaaag tatgtttgga cataatttat	540
aagatgatgc caaagttaaa accagtagaa ctccgagaac ttctgaaccc cggtgtggaa	600
ttcgtttccc atccttctac aacatgttagg gaacaaatgt ataatattct catgtggatt	660
catgataatt acagagatcc agaaaagttag acagataatg actcccagga aatatttaag	720
ttggcaaaag atgtgctgat tcaaggattt atcgatgaga accctggact tcaattaatt	780
attcgaaatt tctggagcca tgaaacttagg ttaccttcaa atactttgg ccgggttgctg	840
gcactaaatt ccttatattc tcctaagata gaagtgcact ttttaagttt agcaacaaat	900
tttctgctcg aaatgaccag catgagccca gattatccaa accccatgtt cgagcatcct	960
ctgtcagaat gcgaatttca ggaatatacc attgattctg attggcggtt ccgaagtact	1020
gttctcaactc cgatgttgtt ggagacccag gcctcccagg gcactctcca gacccgtacc	1080
caggaagggt ccctctcagc tcgctggcca gtggcagggc agataagggc cacccagcag	1140
cagcatgact tcacactgac acagactgca gatggaagaa gctcatgttga ttggctgacc	1200
gggagcagca ctgacccgct ggtcgaccac accagtcctt catctgactc cttgctgttt	1260
gccccacaaga ggagtgaaag gttacagaga gcacccttga agtcagtggg gcctgatttt	1320

<210> 22

<211> 600
<212> DNA
<213> Artificial Sequence

<220>
<223> cDNA sequence encoding the 2500-2700 peptide

<220>
<221> CDS
<222> (1)..(600)
<223> HUMAN GENETIC ORIGIN

<220>
<221> misc_feature
<222> (325)..(327)
<223> encodes T2609 residue

<400> 22

ttggcaaaag atgtgctgat tcaaggattg atcgatgaga accctggact tcaattaatt	60
attcggaaatt tctggagcca tgaaaactagg ttaccccaa ataccttggc ccgggttgctg	120
gcactaaatt ccttatattc tcctaagata gaagtgcact ttttaagttt agcaacaat	180
tttctgctcg aaatgaccag catgagccca gattatccaa accccatgtt cgagcatcct	240
ctgtcagaat gcgaatttca ggaatataacc attgattctg attggcggtt ccgaagtact	300
gttctcactc cgatgttgtt ggagacccag gcctccagg gcactctcca gacccgtacc	360
caggaagggt ccctctcagc tcgctggcca gtggcaggc agataaggc cacccagcag	420
cagcatgact tcacactgac acagactgca gatggaagaa gtcatttga ttggctgacc	480
gggagcagca ctgaccgct ggtcgaccac accagtcct catctgactc cttgctgttt	540
gccccacaaga ggagtgaaag gttacagaga gcacccttga agtcagtggg gcctgatttt	600

<210> 23

<211> 1284
<212> DNA
<213> Artificial sequence

<220>
<223> cDNA sequence encoding 2275-2702 peptide

<220>
<221> CDS
<222> (1)..(1284)
<223> HUMAN GENETIC ORIGIN

<220>
<221> misc_feature
<222> (1003)..(1005)
<223> encodes T2609 residue

<400> 23

caattgctag gcatcgtagt ggccaatgac ctgcctccct atgaccacatc	60
cagagtagcg aataacttcca ggctttgggt aataatatgt cctttgttaag atataaaagaa	120
gtgtatgccg ctgcagcaga agttcttagga cttatacttc gatatgttat ggagagaaaa	180
aacatactgg aggagtctct gtgtgaactg gttgcgaaac aattgaagca acatcagaat	240
actatggagg acaagtttat tgtgtgcttg aacaaagtga ccaagagctt ccctcctctt	300
gcagacaggt tcatgaatgc tgtgttcttt ctgctgcaa aatttcatgg agtgttggaaa	360
acactctgtc tggaggtggt actttgtcgt gtggaggaa tgacagagct gtacttccag	420
ttaaagagca aggacttcgt tcaagtcatg agacatagag atgatgaaag aaaaaaagta	480
tgttggaca taatttataa gatgatgcca aagtaaaac cagtagaact ccgagaactt	540
ctgaaccccg ttgtggaatt cgtttccat ctttctacaa catgtaggaa acaaatgtat	600
aatattctca tgtggattca tgataattac agagatccag aaagtgagac agataatgac	660
tcccaggaaa tatttaagtt ggcaaaagat gtgctgattc aaggattgat cgatgagaac	720
cctggacttc aattaattat tcgaaatttc tggagccatg aaacttaggtt accttcaaatt	780
accttggacc ggttgctggc actaaattcc ttatattctc ctaagataga agtgcacttt	840
ttaagtttag caacaaattt tctgctcgaa atgaccagca tgagcccaga ttatccaaac	900
cccatgttcg agcatcctct gtcagaatgc gaatttcagg aatataccat tgattctgat	960
tggcgttcc gaagtactgt tctcactccg atgtttgtgg agacccaggc ctcccaggc	1020
actctccaga cccgtaccca ggaagggtcc ctctcagctc gctggccagt ggcagggcag	1080
ataagggcca cccagcagca gcatgacttc acactgacac agactgcaga tggagaagc	1140
tcatttgatt ggctgaccgg gagcagcact gaccgcgtgg tcgaccacac cagtcctca	1200
tctgactcct tgctgtttgc ccacaagagg agtgaardgt tacagagagc acccttgaag	1260
tcagtggggc ctgattttgg gaaa	1284

<210> 24

<211> 819

<212> DNA

<213> Artificial Sequence

<220>

<223> cDNA sequence encoding 2429-2072 peptide

<220>

<221> CDS

<222> (1)..(819)

<223> HUMAN GENETIC ORIGIN

<220>

<221> misc_feature

<222> (538)..(540)
<223> encodes T2609 residue

<400> 24

gaaagacaaa aagtatgttt ggacataatt tataagatga tgccaaagtt aaaaccagta	60
gaactccgag aacttctgaa ccccgttgcg gaattcggtt cccatccctc tacaacatgt	120
agggacaaa tgtataatat tctcatgtgg attcatgata attacagaga tccagaaaagt	180
gagacagata atgactccca gaaaaatattt aagttggcaa aagatgtgct gattcaagga	240
ttgatcgatg agaaccctgg acttcaatta attattcgaa atttctggag ccatgaaaact	300
aggtaacctt caaatacctt ggaccggttg ctggcactaa attccttata ttctcctaag	360
atagaagtgc acttttaag ttagcaaca aattttctgc tcgaaaatgac cagcatgagc	420
ccagattatc caaaccctt gttcgagcat cctctgtcag aatgcgaatt tcaggaatat	480
accattgatt ctgattggcg tttccgaagt actgttctca ctccgatgtt tgtggagacc	540
caggcctccc agggcactct ccagaccgt acccaggaag ggtccctctc agctcgctgg	600
ccagtgccag ggcagataag ggccacccag cagcagcatg acttcacact gacacagact	660
gcagatggaa gaagctcatt tgattggctg accgggagca gcactgaccc gctggtcac	720
cacaccagtc cctcatctga ctccttgctg tttgccaca agaggagtga aaggttacag	780
agagcaccct tgaagtcagt ggggcctgat tttggaaaa	819

<210> 25

<211> 420
<212> DNA
<213> Artificial Sequence

<220>
<223> cDNA Sequence encoding 2561-2700 peptide

<220>
<221> CDS
<222> (1)..(420)
<223> HUMAN GENETIC ORIGIN

<220>
<221> misc_feature
<222> (145)..(147)
<223> Encodes T2609 residue

<400> 25

tttctgctcg aaatgaccag catgagccca gattatccaa accccatgtt cgagcatcct	60
ctgtcagaat gcgaatttca ggaatatacc attgattctg attggcggtt ccgaagtact	120
gttctcactc cgatgttgtt ggagacccag gcctccagg gcactctcca gaccgttacc	180

caggaagggt ccctctcagc tcgctggcca gtggcagggc agataagggc caccaggcag	240
cagcatgact tcacactgac acagactgca gatggaagaa gtcatttga ttggctgacc	300
gggagcagca ctgaccgcgt ggtcgaccac accagtccct catctgactc cttgctgttt	360
gcccacacaaga ggagtgaaag gttacagaga gcacccttga agtcagtggg gcctgatttt	420

<210> 26

<211> 306

<212> DNA

<213> Artificial Sequence

<220>

<223> cDNA sequence encoding 2600-2702 peptide

<220>

<221> CDS

<222> (1)..(306)

<223> HUMAN GENETIC ORIGIN

<220>

<221> misc_feature

<222> (25)..(27)

<223> Encodes T2609 residue

<400> 26

gttctcaactc cgatgttgtt ggagacccag gcctcccagg gcactctcca gaccgtacc	60
caggaagggt ccctctcagc tcgctggcca gtggcagggc agataagggc caccaggcag	120
cagcatgact tcacactgac acagactgca gatggaagaa gtcatttga ttggctgacc	180
gggagcagca ctgaccgcgt ggtcgaccac accagtccct catctgactc cttgctgttt	240
gcccacacaaga ggagtgaaag gttacagaga gcacccttga agtcagtggg gcctgatttt	300
gggaaa	306

<210> 27

<211> 34

<212> DNA

<213> Artificial sequence

<220>

<223> Primer to create T2609A mutation

<400> 27

tccgatgttt gtggaggacc aggccctccca gggc	34
--	----

<210> 28

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Reverse primer to create T2609A mutation

<400> 28

gccctgggag gcctggtcct ccacaaacat cgga

34

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US03/12380

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07K 16/40; C12N 9/12; G01N 33/53, 33/573
US CL : 435/7.1, 7.4, 194; 530/388.26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 435/7.1, 7.4, 194; 530/388.26

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DOUG W. CHAN et al.. Ku-Dependent Phosphorylation of the DNA-Dependent Protein Kinase Catalytic Subunit is Required for the Repair of DNA Double Strand Breaks. Ataxiatelangiectasia and ATM, 2002, page 16, see entire document.	1-4,9-18
Y	STEVEN M. YANNONE et al. Werner Syndrome Protein is Regulated and Phosphorylated by DNA-Dependent Protein Kinase. The Journal of Biological Chemistry. 12 October 2001, Vol. 276, No. 41, pages 38242-38248, see entire document.	1-4,9-18

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
*	Special categories of cited documents:		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 21 September 2003 (21.09.2003)	Date of mailing of the international search report 30 SEP 2003
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230	Authorized officer Ron Schwadron, Ph.D. Telephone No. 703 3080196

INTERNATIONAL SEARCH REPORT

PCT/US03/12380

Continuation of B. FIELDS SEARCHED Item 3:

WEST 2.1, MEDICINE/BIOTECH (compendium databases on DIALOG) search terms: inventor names, dna pk, dna dependent protein kinase, phosphoryl?, autophosphoryl?, thr, threonine, ser, serine 2609, 2056, t2609, s2056, ser2056, serine2056, threonine2609, thr2609